A species of gram-negative, aerobic bacteria that is the causative agent of WHOOPING COUGH. Its cells are minute coccobacilli that are surrounded by a slime sheath.
A genus of gram-negative, aerobic bacteria whose cells are minute coccobacilli. It consists of both parasitic and pathogenic species.
A suspension of killed Bordetella pertussis organisms, used for immunization against pertussis (WHOOPING COUGH). It is generally used in a mixture with diphtheria and tetanus toxoids (DTP). There is an acellular pertussis vaccine prepared from the purified antigenic components of Bordetella pertussis, which causes fewer adverse reactions than whole-cell vaccine and, like the whole-cell vaccine, is generally used in a mixture with diphtheria and tetanus toxoids. (From Dorland, 28th ed)
Infections with bacteria of the genus BORDETELLA.
A species of BORDETELLA that is parasitic and pathogenic. It is found in the respiratory tract of domestic and wild mammalian animals and can be transmitted from animals to man. It is a common cause of bronchopneumonia in lower animals.
A respiratory infection caused by BORDETELLA PERTUSSIS and characterized by paroxysmal coughing ending in a prolonged crowing intake of breath.
A set of BACTERIAL ADHESINS and TOXINS, BIOLOGICAL produced by BORDETELLA organisms that determine the pathogenesis of BORDETELLA INFECTIONS, such as WHOOPING COUGH. They include filamentous hemagglutinin; FIMBRIAE PROTEINS; pertactin; PERTUSSIS TOXIN; ADENYLATE CYCLASE TOXIN; dermonecrotic toxin; tracheal cytotoxin; Bordetella LIPOPOLYSACCHARIDES; and tracheal colonization factor.
One of the virulence factors produced by BORDETELLA PERTUSSIS. It is a multimeric protein composed of five subunits S1 - S5. S1 contains mono ADPribose transferase activity.
A species of BORDETELLA with similar morphology to BORDETELLA PERTUSSIS, but growth is more rapid. It is found only in the RESPIRATORY TRACT of humans.
Agents that cause agglutination of red blood cells. They include antibodies, blood group antigens, lectins, autoimmune factors, bacterial, viral, or parasitic blood agglutinins, etc.
One of the virulence factors produced by virulent BORDETELLA organisms. It is a bifunctional protein with both ADENYLYL CYCLASES and hemolysin components.
A species of BORDETELLA isolated from the respiratory tracts of TURKEYS and other BIRDS. It causes a highly contagious bordetellosis.
Vaccines that are produced by using only the antigenic part of the disease causing organism. They often require a "booster" every few years to maintain their effectiveness.
Immunoglobulins produced in a response to BACTERIAL ANTIGENS.
Cell-surface components or appendages of bacteria that facilitate adhesion (BACTERIAL ADHESION) to other cells or to inanimate surfaces. Most fimbriae (FIMBRIAE, BACTERIAL) of gram-negative bacteria function as adhesins, but in many cases it is a minor subunit protein at the tip of the fimbriae that is the actual adhesin. In gram-positive bacteria, a protein or polysaccharide surface layer serves as the specific adhesin. What is sometimes called polymeric adhesin (BIOFILMS) is distinct from protein adhesin.
An enzyme of the lyase class that catalyzes the formation of CYCLIC AMP and pyrophosphate from ATP. EC 4.6.1.1.
A transient increase in the number of leukocytes in a body fluid.
Substances, usually of biological origin, that cause cells or other organic particles to aggregate and stick to each other. They include those ANTIBODIES which cause aggregation or agglutination of particulate or insoluble ANTIGENS.
Proteins isolated from the outer membrane of Gram-negative bacteria.
Proteins found in any species of bacterium.
Combined vaccines consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and an acellular form of PERTUSSIS VACCINE. At least five different purified antigens of B. pertussis have been used in various combinations in these vaccines.
A vaccine consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and whole-cell PERTUSSIS VACCINE. The vaccine protects against diphtheria, tetanus, and whooping cough.
The top portion of the pharynx situated posterior to the nose and superior to the SOFT PALATE. The nasopharynx is the posterior extension of the nasal cavities and has a respiratory function.
Substances elaborated by bacteria that have antigenic activity.
Preparations of pathogenic organisms or their derivatives made nontoxic and intended for active immunologic prophylaxis. They include deactivated toxins. Anatoxin toxoids are distinct from anatoxins that are TROPANES found in CYANOBACTERIA.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
The functional hereditary units of BACTERIA.
The degree of pathogenicity within a group or species of microorganisms or viruses as indicated by case fatality rates and/or the ability of the organism to invade the tissues of the host. The pathogenic capacity of an organism is determined by its VIRULENCE FACTORS.
Excess of normal lymphocytes in the blood or in any effusion.
Any of the processes by which cytoplasmic or intercellular factors influence the differential control of gene action in bacteria.
Deoxyribonucleic acid that makes up the genetic material of bacteria.
Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.
Physicochemical property of fimbriated (FIMBRIAE, BACTERIAL) and non-fimbriated bacteria of attaching to cells, tissue, and nonbiological surfaces. It is a factor in bacterial colonization and pathogenicity.
Low-molecular-weight compounds produced by microorganisms that aid in the transport and sequestration of ferric iron. (The Encyclopedia of Molecular Biology, 1994)
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
Tests that are dependent on the clumping of cells, microorganisms, or particles when mixed with specific antiserum. (From Stedman, 26th ed)
Thin, hairlike appendages, 1 to 20 microns in length and often occurring in large numbers, present on the cells of gram-negative bacteria, particularly Enterobacteriaceae and Neisseria. Unlike flagella, they do not possess motility, but being protein (pilin) in nature, they possess antigenic and hemagglutinating properties. They are of medical importance because some fimbriae mediate the attachment of bacteria to cells via adhesins (ADHESINS, BACTERIAL). Bacterial fimbriae refer to common pili, to be distinguished from the preferred use of "pili", which is confined to sex pili (PILI, SEX).
The formaldehyde-inactivated toxin of Corynebacterium diphtheriae. It is generally used in mixtures with TETANUS TOXOID and PERTUSSIS VACCINE; (DTP); or with tetanus toxoid alone (DT for pediatric use and Td, which contains 5- to 10-fold less diphtheria toxoid, for other use). Diphtheria toxoid is used for the prevention of diphtheria; DIPHTHERIA ANTITOXIN is for treatment.
The cartilaginous and membranous tube descending from the larynx and branching into the right and left main bronchi.
A chronic inflammation in which the NASAL MUCOSA gradually changes from a functional to a non-functional lining without mucociliary clearance. It is often accompanied by degradation of the bony TURBINATES, and the foul-smelling mucus which forms a greenish crust (ozena).
Regulatory proteins that act as molecular switches. They control a wide range of biological processes including: receptor signaling, intracellular signal transduction pathways, and protein synthesis. Their activity is regulated by factors that control their ability to bind to and hydrolyze GTP to GDP. EC 3.6.1.-.
Toxic substances formed in or elaborated by bacteria; they are usually proteins with high molecular weight and antigenicity; some are used as antibiotics and some to skin test for the presence of or susceptibility to certain diseases.
An ester formed between the aldehydic carbon of RIBOSE and the terminal phosphate of ADENOSINE DIPHOSPHATE. It is produced by the hydrolysis of nicotinamide-adenine dinucleotide (NAD) by a variety of enzymes, some of which transfer an ADP-ribosyl group to target proteins.
The tubular and cavernous organs and structures, by means of which pulmonary ventilation and gas exchange between ambient air and the blood are brought about.
Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease.
Proteins from BACTERIA and FUNGI that are soluble enough to be secreted to target ERYTHROCYTES and insert into the membrane to form beta-barrel pores. Biosynthesis may be regulated by HEMOLYSIN FACTORS.
Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood.
Antisera from immunized animals that is purified and used as a passive immunizing agent against specific BACTERIAL TOXINS.
An adenine nucleotide containing one phosphate group which is esterified to both the 3'- and 5'-positions of the sugar moiety. It is a second messenger and a key intracellular regulator, functioning as a mediator of activity for a number of hormones, including epinephrine, glucagon, and ACTH.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions.
Discrete segments of DNA which can excise and reintegrate to another site in the genome. Most are inactive, i.e., have not been found to exist outside the integrated state. DNA transposable elements include bacterial IS (insertion sequence) elements, Tn elements, the maize controlling elements Ac and Ds, Drosophila P, gypsy, and pogo elements, the human Tigger elements and the Tc and mariner elements which are found throughout the animal kingdom.

Role of antibodies against Bordetella pertussis virulence factors in adherence of Bordetella pertussis and Bordetella parapertussis to human bronchial epithelial cells. (1/1244)

Immunization with whole-cell pertussis vaccines (WCV) containing heat-killed Bordetella pertussis cells and with acellular vaccines containing genetically or chemically detoxified pertussis toxin (PT) in combination with filamentous hemagglutinin (FHA), pertactin (Prn), or fimbriae confers protection in humans and animals against B. pertussis infection. In an earlier study we demonstrated that FHA is involved in the adherence of these bacteria to human bronchial epithelial cells. In the present study we investigated whether mouse antibodies directed against B. pertussis FHA, PTg, Prn, and fimbriae, or against two other surface molecules, lipopolysaccharide (LPS) and the 40-kDa outer membrane porin protein (OMP), that are not involved in bacterial adherence, were able to block adherence of B. pertussis and B. parapertussis to human bronchial epithelial cells. All antibodies studied inhibited the adherence of B. pertussis to these epithelial cells and were equally effective in this respect. Only antibodies against LPS and 40-kDa OMP affected the adherence of B. parapertussis to epithelial cells. We conclude that antibodies which recognize surface structures on B. pertussis or on B. parapertussis can inhibit adherence of the bacteria to bronchial epithelial cells, irrespective whether these structures play a role in adherence of the bacteria to these cells.  (+info)

Role of Bordetella pertussis virulence factors in adherence to epithelial cell lines derived from the human respiratory tract. (2/1244)

During colonization of the respiratory tract by Bordetella pertussis, virulence factors contribute to adherence of the bacterium to the respiratory tract epithelium. In the present study, we examined the roles of the virulence factors filamentous hemagglutinin (FHA), fimbriae, pertactin (Prn), and pertussis toxin (PT) in the adherence of B. pertussis to cells of the human bronchial epithelial cell line NCI-H292 and of the laryngeal epithelial cell line HEp-2. Using B. pertussis mutant strains and purified FHA, fimbriae, Prn, and PT, we demonstrated that both fimbriae and FHA are involved in the adhesion of B. pertussis to laryngeal epithelial cells, whereas only FHA is involved in the adherence to bronchial epithelial cells. For PT and Prn, no role as adhesion factor was found. However, purified PT bound to both bronchial and laryngeal cells and as such reduced the adherence of B. pertussis to these cells. These data may imply that fimbriae play a role in infection of only the laryngeal mucosa, while FHA is the major factor in colonization of the entire respiratory tract.  (+info)

Characterization of human bactericidal antibodies to Bordetella pertussis. (3/1244)

The Bordetella pertussis BrkA protein protects against the bactericidal activity of complement and antibody; however, some individuals mount an immune response that overcomes this bacterial defense. To further characterize this process, the bactericidal activities of sera from 13 adults with different modes of exposure to B. pertussis (infected as adults, occupational exposure, immunized with an acellular vaccine, or no identified exposure) against a wild-type strain and a BrkA complement-sensitive mutant were evaluated. All of the sera killed the BrkA mutant, suggesting past exposure to B. pertussis or cross-reactive organisms. Several samples had no or minimal activity against the wild type. All of the sera collected from the infected and occupationally exposed individuals but not all of the sera from vaccinated individuals had bactericidal activity against the wild-type strain, suggesting that some types of exposure can induce an immune response that can overcome the BrkA resistance mechanism. Adsorbing serum with the wild-type strain removed the bactericidal antibodies; however, adsorbing the serum with a lipopolysaccharide (LPS) mutant or an avirulent (bvg mutant) strain did not always result in loss of bactericidal activity, suggesting that antibodies to either LPS or bvg-regulated proteins could be bactericidal. All the samples, including those that lacked bactericidal activity, contained antibodies that recognized the LPS of B. pertussis. Bactericidal activity correlated best with the presence of the immunoglobulin G3 (IgG3) antibodies to LPS, the IgG subtype that is most effective at fixing complement.  (+info)

Maternal immunization. (4/1244)

Maternal immunization can enhance passive immunity of infants to pathogens that cause life-threatening illnesses. In most instances, immunization during pregnancy will provide important protection for the woman as well as for her offspring. The tetanus toxoid and influenza vaccines are examples of vaccines that provide a double benefit. Other vaccines under evaluation include those for respiratory syncytial virus, pneumococci, group B streptococci, and Haemophilus influenzae type b. Although most IgG antibody crosses the placenta in the third trimester, the process is time-dependent, dictating that immunization should be accomplished ideally at least 6 weeks prior to delivery. IgG1 antibodies are transferred preferentially. Maternal immunization has not interfered with active immunization of the infant. Inactivated vaccines administered in the third trimester of pregnancy pose no known risk to the woman or to her fetus.  (+info)

Temporal trends in the population structure of Bordetella pertussis during 1949-1996 in a highly vaccinated population. (5/1244)

The population structure of Bordetella pertussis in The Netherlands in 5 successive periods, encompassing 1949-1996, was analyzed by DNA typing ("fingerprinting"). In 10 years following the introduction of wide-scale vaccination in 1953, a decrease in genotypic diversity (GD) was observed, suggesting clonal expansion of strains that were adapted to vaccine-induced immunity. In subsequent periods, GD increased to prevaccination levels, probably reflecting a gradual adaptation of the B. pertussis population involving many lineages. In the 1990s, GD decreased again. This decrease coincided with an antigenic shift in the surface protein pertactin. No evidence was found for changes in DNA types or GD in 1996, when a large pertussis epidemic occurred. Thus, gradual changes in the bacterial population previous to 1996 were probably the cause of the 1996 epidemic. The results herein suggest that vaccination has selected for strains that are adapted to a highly vaccinated population. Similar changes may have occurred in other countries, explaining the reemergence of pertussis in vaccinated populations.  (+info)

Analysis with a combination of macrorestriction endonucleases reveals a high degree of polymorphism among Bordetella pertussis isolates in eastern France. (6/1244)

From 1990 to 1996, routine screening for whooping cough identified 399 patients with a calmodulin-dependent adenylate cyclase-positive test result and yielded 69 Bordetella pertussis isolates. None of the patients were fully vaccinated, and most were less than 6 months old. Analysis of total DNA by pulsed-field gel electrophoresis (PFGE) after XbaI, SpeI, or DraI macrorestriction yielded 19, 15, and 5 different patterns, respectively, whereas ribotyping failed to demonstrate any strain polymorphism. Discrimination among the isolates was improved by combining the PFGE profiles. Some patterns were more frequent, but the corresponding patients were not clearly epidemiologically related. The patterns for two strains obtained during a 3-month period from patients who were neighbors differed by the length of a single DNA fragment. These data strongly suggest that one type of isolate is widely spread throughout the world and is carried by individuals other than patients who develop a true illness.  (+info)

Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis. (7/1244)

Levels of IgG antibody to pertussis toxin (PT) and filamentous hemagglutinin (FHA) were measured in paired serum samples from 781 patients fulfilling at least one laboratory criterion for pertussis that was suggested by an ad hoc committee sponsored by the World Health Organization. The patients were participants or family members of participants in a double-blind efficacy trial of a monocomponent pertussis toxoid vaccine. Of 596 nonvaccinated children, 90% had significant (two-fold or more) rises in PT IgG and FHA IgG levels. Only 17 (32%) of 53 children previously vaccinated with three doses of pertussis toxoid had rises in PT IgG levels because they already had elevated PT IgG levels in their acute-phase serum samples. PT IgG and FHA IgG levels were significantly higher in acute-phase serum samples from 29 adults than in acute-phase serum samples from the nonvaccinated children. Nevertheless, significant rises in levels of PT IgG (79% of samples) and FHA IgG (90%) were demonstrated in adults. In conclusion, assay of PT IgG and FHA IgG in paired serum samples is highly sensitive for diagnosing pertussis in nonvaccinated individuals. Assay of PT IgG levels in paired sera is significantly less sensitive for diagnosis of pertussis for children vaccinated with pertussis toxoid.  (+info)

The conserved lysine 860 in the additional fatty-acylation site of Bordetella pertussis adenylate cyclase is crucial for toxin function independently of its acylation status. (8/1244)

The Bordetella pertussis RTX (repeat in toxin family protein) adenylate cyclase toxin-hemolysin (ACT) acquires biological activity upon a single amide-linked palmitoylation of the epsilon-amino group of lysine 983 (Lys983) by the accessory fatty-acyltransferase CyaC. However, an additional conserved RTX acylation site can be identified in ACT at lysine 860 (Lys860), and this residue becomes palmitoylated when recombinant ACT (r-Ec-ACT) is produced together with CyaC in Escherichia coli K12. We have eliminated this additional acylation site by replacing Lys860 of ACT with arginine, leucine, and cysteine residues. Two-dimensional gel electrophoresis and microcapillary high performance liquid chromatography/tandem mass spectrometric analyses of mutant proteins confirmed that the two sites are acylated independently in vivo and that mutations of Lys860 did not affect the quantitative acylation of Lys983 by palmitoyl (C16:0) and palmitoleil (cis Delta9 C16:1) fatty-acyl groups. Nevertheless, even the most conservative substitution of lysine 860 by an arginine residue caused a 10-fold decrease of toxin activity. This resulted from a 5-fold reduction of cell association capacity and a further 2-fold reduction in cell penetration efficiency of the membrane-bound K860R toxin. These results suggest that lysine 860 plays by itself a crucial structural role in membrane insertion and translocation of the toxin, independently of its acylation status.  (+info)

Bordetella pertussis adenylate cyclase. Penetration into host cells.: Exposure of Chinese hamster ovary, mouse adrenal cortex tumor (Y-1), THP-1 and U-937 cells
The Bordetella pertussis calmodulin-dependent adenylate cyclase (CyaA) is a 1706-residue-long toxin, endowed with hemolytic activity. We have constructed B.
The effect of an i.p. injection of Bordetella pertussis on the primary humoral immune response in mice to the thymus-independent antigen SIII has been studied. Suppression of the antibody response occurred when pertussis cells were injected at the same time as an optimal immunizing dose of SIII. In contrast, the antibody response to high doses of SIII was enhanced by B. pertussis.. When SIII alone was injected, only 19S antibody was detected. However, when B. pertussis was administered with either optimal or high doses of SIII, 7S as well as 19S antibody against SIII was produced.. ...
Bordetella pertussis isolates that do not express pertactin (PRN) are increasing in regions where acellular pertussis vaccines have been used for >7 years. We analyzed data from France and compared clinical symptoms among infants <6 months old infected by PRN-positive or PRN-negative isolates. No major clinical differences were found between the 2 groups.
Bordetella pertussis is the causative agent of human whooping cough (pertussis) and is particularly severe in infants. Despite worldwide vaccinations, whooping cough remains a public health problem. A significant increase in the incidence of whooping cough has been observed in many countries since the 1990s. Several reasons for the re-emergence of this highly contagious disease have been suggested. A particularly intriguing possibility is based on evidence indicating that pathogen adaptation may play a role in this process. In an attempt to gain insight into the genomic make-up of B. pertussis over the last 60 years, we used an oligonucleotide DNA microarray to compare the genomic contents of a collection of 171 strains of B. pertussis isolates from different countries. The CGH microarray analysis estimated the core genome of B. pertussis, to consist of 3,281 CDSs that are conserved among all B. pertussis strains, and represent 84.8% of all CDSs found in the 171 B. pertussis strains. A total of 64
Morse, J.H.; Kong, A.S.; Lindenbaum, J.; Morse, S.I., 1977: The mitogenic effect of the lymphocytosis promoting factor from Bordetella pertussis on human lymphocytes
The effect of exogenously added adenylate cyclase from Bordetella pertussis (strain 114) has been investigated in Y-1 mouse adrenal tumor, chinese hamster ovary (CHO) and several other cells. A partially purified adenylate cyclase was found not to enter cells but, nevertheless, produced large amounts of cAMP in the medium. We could show that this resulted from release of ATP (and not larger molecules). The ATP released by the cells could be (1) directly measured and was replenished after each change of medium; (2) was reciprocally related to the cAMP produced; and (3) was competed for by ATPases present in added serum or by hexokinase and, less effectively, by exoenzymes on the cell surface. The extent of ATP leakage varied widely between different cell lines, being marked in CHO and Y-1 adrenal cells but negligible in transformed lymphocyte lines. The uncertainty of the origin of cAMP found in media of cultured cells requires separate analysis of cell and medium cAMP and an assessment of ATP ...
Since the 1980s, pertussis notifications in the United States have been increasing. To determine the types of Bordetella pertussis responsible for these increases, we divided 661 B. pertussis isolates collected in the United States during 1935-2009 into 8 periods related to the introduction of novel vaccines or changes in vaccination schedule. B. pertussis diversity was highest from 1970-1990 (94%) but declined to ≈ 70% after 1991 and has remained constant. During 2006-2009, 81.6% of the strains encoded multilocus sequence type prn2-ptxP3-ptxS1A-fim3B, and 64% were multilocus variable number tandem repeat analysis type 27. US trends were consistent with those seen internationally; emergence and predominance of the fim3B allele was the only molecular characteristic associated with the increase in pertussis notifications. Changes in the vaccine composition and schedule were not the direct selection pressures that resulted in the allele changes present in the current B. pertussis population ...
Acellular vaccines against Bordetella pertussis were introduced in Australia in 1997. By 2000, these vaccines had replaced whole-cell vaccines. During 2008-2012, a large outbreak of pertussis occurred. During this period, 30% (96/320) of B. pertussis isolates did not express the vaccine antigen pertactin (prn). Multiple mechanisms of prn inactivation were documented, including IS481 and IS1002 disruptions, a variation within a homopolymeric tract, and deletion of the prn gene. The mechanism of lack of expression of prn in 16 (17%) isolates could not be determined at the sequence level. These findings suggest that B. pertussis not expressing prn arose independently multiple times since 2008, rather than by expansion of a single prn-negative clone. All but 1 isolate had ptxA1, prn2, and ptxP3, the alleles representative of currently circulating strains in Australia. This pattern is consistent with continuing evolution of B. pertussis in response to vaccine selection pressure.
The genus Bordetella consists of Gram-negative β-proteobacteria, including the three human pathogens Bordetella pertussis, Bordetella parapertussis an...
TY - JOUR. T1 - Surveillance of circulating bordetella pertussis strains in Europe during 1998 to 2015. AU - Barkoff, Alex Mikael. AU - Mertsola, Jussi. AU - Pierard, Denis. AU - Dalby, Tine. AU - Hoegh, Silje Vermedal. AU - Guillot, Sophie. AU - Stefanelli, Paola. AU - Van Gent, Marjolein. AU - Berbers, Guy. AU - Vestrheim, Didrik F.. AU - Greve-Isdahl, Margrethe. AU - Wehlin, Lena. AU - Ljungman, Margaretha. AU - Fry, Norman. AU - Markey, Kevin. AU - Auranen, Kari. AU - Hea, Qiushui. N1 - Funding Information: eDepartment of Clinical Microbiology, Odense, University Hospital, Odense, Denmark fNational Reference Center of Whooping Cough and Other Bordetelloses, Institut Pasteur, Paris, France gDepartment of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy hCentre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands Publisher Copyright: Copyright © 2018 American Society for Microbiology. All Rights ...
Bordetella pertussis infection is being increasingly recognized as a cause of prolonged, distressing cough (without whooping symptoms) in children and young adults. Diagnosis of infection in this population is important for treatment and surveillance purposes, and may also prove useful in reducing transmission to unvaccinated babies, for whom disease can be fatal. Serum IgG titres against pertussis toxin (PT) are routinely used as a marker of recent or persisting B. pertussis infection. However, collection of serum from young children is difficult, and compliance amongst these subjects to give samples is low. To circumvent these problems, an IgG-capture ELISA capable of detecting anti-PT IgG in oral fluid was devised. The assay was evaluated by comparison to a serum ELISA, using 187 matched serum and oral fluid samples from children (aged 5-16 years) with a history of prolonged coughing, whose serum anti-PT titre had already been determined (69 seropositive, 118 seronegative). The results showed that,
Bordetella pertussis is an aerobic gram-negative bacterial pathogen that causes the human respiratory disease whooping cough. Despite widespread vaccination, whooping cough is reemerging due to decreased vaccine efficacy. One of the hallmarks of infection is lymphocytosis, which is induced by the pertussis toxin. Lymphocytes such as CD4+ T cells navigate to infected tissues through surface-trafficking molecules, which are imprinted during their interaction with tissue-associated dendritic cells. We hypothesized that the pertussis toxin affects the imprinting process resulting in altered expression of trafficking molecules on CD4+ T cells. We tested this hypothesis using a mouse model of infection. Imprinting levels on CD4+ T cells were compared to Bordetella parapertussis, a related strain that lacks pertussis toxin. Our results indicated that 5 days post-infection, the percentage of lung dendritic cells increased and adopted a mature phenotype (displaying an increased capability to migrate and present
TY - JOUR. T1 - Intracellular survival of virulent Bordetella pertussis in human polymorphonuclear leukocytes. AU - Steed, L. L.. AU - Setareh, M.. AU - Friedman, R. L.. PY - 1991/1/1. Y1 - 1991/1/1. N2 - Little is known regarding the interaction of Bordetella pertussis with polymorphonuclear leukocytes (PMNL) or the role PMNL play as an initial line of defense against B. pertussis infection. An in vitro system was developed to establish conditions for the study of phagocytosis and killing of virulent B. pertussis by human PMNL. Phagocytosis of B. pertussis strains BP504, BP165, and BP338 occurred by opsonization with anti-B. pertussis antibody, while autologous normal human sera did not induce significant phagocytosis. In PMNL bacterial killing assays virulent B. pertussis strains survived PMNL bactericidal activities while Escherichia coli controls were readily killed. Electron microscopy studies using acid phosphatase as a lysosomal marker strongly suggested that B. pertussis inhibits ...
Bordetella pertussis is a strict human pathogen that is the causative agent of pertussis (whooping cough). Despite widespread immunization with pertussis vaccines, many countries still report outbreaks (1, 12, 14). Resurgence of pertussis has been recently observed in some countries with high vaccination coverage (4, 8, 10). It is suggested that pathogen adaptation may play a role in the reemergence of pertussis (10, 15, 16). In this present work, the complete genome sequence of B. pertussis strain CS, which was isolated from an infant patient in 1951 in Beijing and widely used as a vaccine strain for production of an acellular pertussis vaccine in China, was determined and compared with the published genome of Tohama I (11).. Whole-genome sequencing of B. pertussis CS was performed with a combined strategy of the Sanger shotgun approach (6) and 454 fragment sequencing technology (9). A total of 329,480 reads, giving 28-fold coverage of the genome, were generated using the GS FLX system (454 ...
Bordetella pertussis ATCC ® BAA-589D-5™ Designation: Genomic DNA from Bordetella pertussis Strain Tohama 1 TypeStrain=False Application:
The Global and Chinese Bordetella Pertussis Industry, 2011-2021 Market Research Report is a professional and in-depth study on the current state of the global Bordetella Pertussis industry with a focus on the Chinese market. The report provides key statistics on the market status of the Bordetella Pertussis manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.. Complete report of 150 pages published in Jan 2016 is available at http://www.market-research-reports.com/434778-bordetella-pertussis-industry.. Firstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology. Then, the report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2011-2016 market shares for each company. Through the statistical analysis, the report depicts the ...
BACKGROUND: Each year, Bordetella pertussis infection causes an estimated 294,000 deaths worldwide, primarily among young, nonvaccinated children. Approximately 90% of all deaths due to pertussis in the Unites States occur in young infants. These children often develop intractable pulmonary hypertension; however, the pathophysiologic mechanism responsible for this complication has not been well characterized, and there have been no detailed descriptions of the pathology of this disease since the 1940s.. METHODS: Respiratory tissue samples obtained at autopsy from 15 infants aged ,or=4 months who had polymerase chain reaction- or culture-confirmed B. pertussis pneumonia were evaluated by multiple histochemical stains, immunohistochemical evaluation, and electron microscopic examination.. RESULTS: The pulmonary histopathologic examination of the samples revealed a descending infection dominated by necrotizing bronchiolitis, intra-alveolar hemorrhage, and fibrinous edema. All samples had marked ...
Catalyzes the rearrangement of 1-deoxy-D-xylulose 5-phosphate (DXP) to produce the thiazole phosphate moiety of thiamine. Sulfur is provided by the thiocarboxylate moiety of the carrier protein ThiS. In vitro, sulfur can be provided by H(2)S.
Intranasal immunization of adult female Balb/c mice with the Bordetella pertussis antigens FHA or P.69, greatly enhanced their ability to clear B. pertussis from their lungs following aerosol challenge compared with ovalbumin-immunized controls. Low numbers of lymphocytes secreting antibodies (IgG, …
In order to achieve batch-to-batch consistency of whole-cell pertussis vaccines, properties relevant for protection and safety should be characterised. Therefore, ELISAs to quantify pertussis toxin (PT), filamentous haemagglutinin (FHA), 92 kD outer membrane protein (92 kD-OMP) and pertactin (PRN) in Bordetella pertussis (B. pertussis) suspensions were developed. In this paper the influence of the bacterial growth stage on antigen production and antigen release into the supernatant was studied for pertussis strains 134, 509 and CS. The levels of cell-associated and free antigens during growth were strongly strain and antigen dependent. Because of this, the proportion of cell-associated antigens changed during cultivation for all three strains. Substantial amounts of PT and PRN were released into the supernatant, while little free FHA and 92 kD-OMP were found. The amount of cell-associated FHA declined rapidly during growth, whereas cell-associated 92 kD-OMP contents increased. These findings ...
OBJECTIVE: To study the clinical presentation of culture-confirmed pertussis in children and their contacts with cough illnesses in an outpatient setting. METHODOLOGY: In conjunction with a large pertussis vaccine efficacy trial in Germany, a central laboratory to isolate Bordetella species from nasopharyngeal specimens was established in Erlangen in October 1990. Pediatricians in private practices in southern Germany, the Saar region, and Berlin were encouraged to obtain nasopharyngeal specimens and clinical characteristics from patients with cough illnesses ,/=7 days duration. Bordetella species were isolated by use of calcium alginate swabs, Regan-Lowe agar, and modified Stainer-Scholte broth. Clinical characteristics were determined by initial and follow-up questionnaires. RESULTS: From October 1990 to September 1996, 20 972 specimens were submitted, and B pertussis was isolated in 2592 instances (12.4%). Of the culture-proven cases, 50.7% were female, and the age range was 6 days to 41 ...
Bordetella pertussis, small coccoid gram-negative rod-shaped bacteria, is the causative agent of pertussis, a respiratory disease. The bacteria are transmitted by droplet infection from individual to individual. The disease mainly affects children in the age of 0-4 years. It shows a high lethality in newborns. The Immunolab Bordetella pertussis IgG/IgM/IgA ELISAs are quantitative and qualitative tests for the…
Background. Acellular pertussis (aP) booster immunizations have been recommended for adolescents and older persons to enhance long-term protection and to possibly reduce community transmission of infections.. Methods. This was a multicenter, randomized, double-blind vaccine trial in which one-half of the subjects received aP vaccine and one-half received hepatitis A vaccine (control subjects). All subjects were observed for almost 2 years for cough illnesses, and all underwent microbiologic and serologic studies for detection of pertussis infection. Immunoglobulin G (IgG) and immunoglobulin A (IgA) antibodies to pertussis toxin, filamentous hemagglutinin, pertactin, and fimbriae 2/3 were measured by enzyme-linked immunosorbent assay in serum samples obtained 1 and 12 months after immunization. Infection rates were determined with a variety of serologic criteria for control and vaccinated subjects. The incidence of prolonged cough illness was ascertained for subjects with and subjects without ...
GENTILE, Ángela et al. Cost of Bordetella pertussis illness in tertiary hospitals in Argentina. Arch. argent. pediatr. [online]. 2013, vol.111, n.4, pp.295-302. ISSN 0325-0075. http://dx.doi.org/10.5546/aap.2013.295.. The National Immunization Commission and the National Program for the Control of Vaccine-Preventable Diseases (Programa Nacional de Control de Enfermedades Inmunoprevenibles, ProNaCEI) updated the immunization policy in relation to Bordetella pertussis (BP) in 2009 in order to improve the control of this disease in accordance with international recommendations. To evaluate the fnancial impact of this new immunization policy, we must frst know the cost on the health system of having a hospitalized or outpatient child infected with BP. The objective of this study was to describe the profle of costs of hospitalized or outpatient children with laboratory-confrmed BP infection in three hospitals of Argentina. This was a prospective study of the cost of BP in the period between December ...
ID BOPER1_1_PE1000 STANDARD; PRT; 266 AA. AC BOPER1_1_PE1000; Q7VZ03; DT 00-JAN-0000 (Rel. 1, Created) DT 00-JAN-0000 (Rel. 2, Last sequence update) DT 00-JAN-0000 (Rel. 3, Last annotation update) DE SubName: Full=Competence lipoprotein; (BOPER1_1.PE1000). GN Name=comL; OrderedLocusNames=BP1146; OS BORDETELLA PERTUSSIS TOHAMA I. OC Bacteria; Proteobacteria; Betaproteobacteria; Burkholderiales; OC Alcaligenaceae; Bordetella. OX NCBI_TaxID=257313; RN [0] RP -.; RG -.; RL -.; CC -!- SEQ. DATA ORIGIN: Translated from the HOGENOM CDS BOPER1_1.PE1000. CC Bordetella pertussis Tohama I, complete genome. CC complete sequence. CC -!- ANNOTATIONS ORIGIN:Q7VZ03_BORPE CC -!- GENE_FAMILY: HOG000260923 [ FAMILY / ALN / TREE ] DR UniProtKB/Swiss-Prot; Q7VZ03; -. DR EMBL; BX640414; CAE41443.1; -; Genomic_DNA. DR RefSeq; NP_879922.1; NC_002929.2. DR GeneID; 2665391; -. DR GenomeReviews; BX470248_GR; BP1146. DR KEGG; bpe:BP1146; -. DR OMA; IHVADYY; -. DR PhylomeDB; Q7VZ03; -. DR ProtClustDB; CLSK920261; -. DR GO; ...
What is pertussis (whooping cough)? Pertussis (also called whooping cough) is a disease caused by the bacteria Bordetella pertussis that spreads from person-to-person with close contact. It may cause severe coughing fits which can affect breathing. Pertussis is often milder in older children and adults, but can cause serious problems in infants. Pertussis can lead to pneumonia, convulsions, inflammation of the brain and sometimes death. Most of these serious problems occur in infants who are less than one year old. Who can get pertussis? Pertussis can occur in any age group; however, pertussis is more common among infants since they are too young to have full protection from the vaccine. Pertussis is also more common in adolescents and adults who have lost the protection they got from vaccination or illness in childhood. How is pertussis spread? Pertussis is spread from one person to another through respiratory droplets from the nose or throat of an infected person by coughing or sneezing, and ...
Mooi FR; van Loo IHM; van Gent M; He Q; Bart MJ; Heuvelman KJ; de Greeff SC; Diavatopoulos D; Teunis P; Nagelkerke N; Mertsola J (2009 ...
Bordetella pertussis Antibodies, IgA, IgG, & IgM,ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories client,medicine,medical supply,medical supplies,medical product
CyaA, the adenylate cyclase toxin from Bordetella pertussis, can deliver its N-terminal catalytic domain into the cytosol of a large number of eukaryotic
Despite the availability of highly effective vaccines, Bordetella pertussis incidence has been rapidly rising in highly vaccinated populations. Recent outbreaks have received media attention, feeding concerns about the emergence of dangerous new strains with increased virulence or that escape vaccine-induced immunity. To accelerate the study of this reemerging pathogen, we sequenced the genomes of 28 B. pertussis strains isolated during outbreaks from 2010 through 2012, making both strains and sequence data available to the scientific community ...
IDENTIFICATION AND USE: a simple chemically defined medium for the production of phase 1 Bordetella Pertussis described consisting of sodium glutamate, proline, cystine, salts, and growth factors, which is suitable for the large-scale production of phase 1 bordetella pertussis. The cultures were detoxified by the addition of 0.14% formalin. The acellular pertussis antigens (PT, FHA, and pertactin) are isolated from Bordetella pertussis culture grown in modified Stainer-Scholte liquid medium. PT and FHA are isolated from the fermentation broth; pertactin is extracted from the cells by heat treatment and flocculation. The antigens are purified in successive chromatographic and precipitation steps. PT is detoxified using glutaraldehyde and formaldehyde. FHA and pertactin are treated with formaldehyde. Each antigen is individually adsorbed onto aluminum hydroxide. Each 0.5-mL dose is formulated to contain 5 Lf of tetanus toxoid, 2.5 Lf of diphtheria toxoid, 8 mcg of inactivated PT, 8 mcg of FHA, and ...
Bordetella pertussis, the human pathogen of whooping cough, when grown at 22 degrees C is nonvirulent and unable to bind eukaryotic cells. In response to a temperature shift to 37 degrees C, the bacterium acquires the ability to bind eukaryotic cells in a time-dependent fashion. By studying in vitro the temperature-induced transition, from the nonvirulent to the virulent state, we found that binding to CHO cells is mediated by the Arg-Gly-Asp-containing domain of filamentous hemagglutinin (FHA), a protein with multiple binding specificities. This protein is synthesized as a 367-kDa polypeptide within 10 min after temperature shift, but requires 2 hr before it is detected on the bacterial cell surface and starts to bind CHO cells. Mutations affecting the cell surface export of FHA abolish bacterial adhesion to CHO cells, while mutations in the outer membrane protein pertactin strongly reduce binding. This suggests that multiple chaperon proteins are required for a correct function of FHA. ...
A mouse immunoglobulin G3 monoclonal antibody specific for the core oligosaccharide moiety of the lipooligosaccharide (LOS) of Bordetella pertussis has been shown to have complement-dependent bactericidal activity. This monoclonal antibody exhibits bactericidal activity against strains of B. pertussis that express the LOS A phenotype. In addition this monoclonal antibody was effective in reducing colonization by B. pertussis in both the lungs and tracheas of mice after aerosol infection. ...
Bordetella pertussis ASR,The B. pertussis ASR contains primers and a FAM-labeled probe that is designed to detect a 103 bp region of the IS481 gene. In addition, the B. pertussis ASR contains primers, a Texas Red-labeled probe and DNA for an internal control sequence. This ASR requires an instrument that can detect FAM and,medicine,medical supply,medical supplies,medical product
Pertussis (whooping cough) is a disease of uncontrollable coughing as a result of infection caused by bacteria Bordetella pertussis Types of food to prevent and treat Pertussis 1. Green tea and black tea In the study to evaluate the efficacy of anti bactericidal activity of tea and catechins against Bordetella pertussis, indicated that pu-erh tea …. ...
Pertussis toxin (PT) is a protein-based AB5-type exotoxin produced by the bacterium Bordetella pertussis, which causes whooping cough. PT is involved in the colonization of the respiratory tract and the establishment of infection. Research suggests PT may have a therapeutic role in treating a number of common human ailments, including hypertension, viral inhibition, and autoimmune inhibition. PT clearly plays a central role in the pathogenesis of pertussis although this was discovered only in the early 1980s. The appearance of pertussis is quite recent, compared with other epidemic infectious diseases. The earliest mention of pertussis, or whooping cough, is of an outbreak in Paris in 1414. This was published in Moultons The Mirror of Health, in 1640. Another epidemic of pertussis took place in Paris in 1578 and was described by a contemporary observer, Guillaume de Baillou. Pertussis was well known throughout Europe by the middle of the 18th century. Jules Bordet and Octave Gengou described in ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Banked acute-phase and convalescent-phase serum samples from a previous study of respiratory illness in university students were examined for significant (≥2-fold) increases in ELISA titers of IgA and IgG antibody to Bordetella pertussis filamentous hemagglutinin, pertactin, and fimbriae-2 and ≥4-fold titer increases to agglutinogens by agglutination. ELISA titers of antibody to pertussis toxin could not be determined because of technical problems. Chlamydia pneumoniae infections were diagnosed by culture or by a ≥4-fold increase in immunofluorescence assay titer or a single high titer (≥512). Mycoplasma pneumoniae, influenza A and B, adenovirus, and respiratory syncytial virus infections were diagnosed by ≥4-fold increases in complement fixation titer or a single high titer (≥64). There were 319 subjects with cough of ≥5 days duration, and of these, 47 (15%) had significant increases in antibody to B. pertussis antigens; 26 (8%) had significant increases to fimbriae-2 or ...
p>The checksum is a form of redundancy check that is calculated from the sequence. It is useful for tracking sequence updates.,/p> ,p>It should be noted that while, in theory, two different sequences could have the same checksum value, the likelihood that this would happen is extremely low.,/p> ,p>However UniProtKB may contain entries with identical sequences in case of multiple genes (paralogs).,/p> ,p>The checksum is computed as the sequence 64-bit Cyclic Redundancy Check value (CRC64) using the generator polynomial: x,sup>64,/sup> + x,sup>4,/sup> + x,sup>3,/sup> + x + 1. The algorithm is described in the ISO 3309 standard. ,/p> ,p class=publication>Press W.H., Flannery B.P., Teukolsky S.A. and Vetterling W.T.,br /> ,strong>Cyclic redundancy and other checksums,/strong>,br /> ,a href=http://www.nrbook.com/b/bookcpdf.php>Numerical recipes in C 2nd ed., pp896-902, Cambridge University Press (1993),/a>),/p> Checksum:i ...
Pertussis (Whooping Cough). Pertussis is a highly contagious respiratory disease caused by the bacteria Bordetella pertussis. Pertussis lives in the nose, mouth, and throat of infected individuals. The bacteria are shed in nasopharyngeal secretions and can be spread through coughing, sneezing, or direct contact with fluids from the nose, mouth, or throat of an infected person. If untreated, infected individuals can spread the pertussis bacteria to others from 1 week before cough onset to 21 days after cough onset. Untreated infants (,1 year) remain infectious for up to 42 days from cough onset. When treated with antibiotics, the infectious period is reduced to 5 days after the initiation of treatment. Severe infections can result in complications such as pneumonia among all age groups. Seizures and encephalopathy generally occur only among infants. The average incubation period for pertussis is 7-10 days with a range of 4-21 days.. Case Definition. A cough illness lasting ≥2 weeks with at ...
Escaneado de imágenes de microscopio electrónico de Bordetella pertussis - Gram-negativa, aerobia, no móviles, cocobacilos procariotas (bacterias) que causa la tosferina o pertussis. Sobre la técnica de imagen: Las tecnologías modernas tales como la microscopía electrónica puede dar detalles más finos de las bacterias que la microscopía óptica (luz) e incluso puede ser utilizado para mostrar las características internas. Las micrografías electrónicas son imágenes en blanco y negro generados por los rayos de alta energía de electrones. Las micrografías a veces se les da un color falso para que sean visualmente atractivo (en este caso, se utilizó un tinte verde).. ...
The heterohybridoma cell line HBp2 secreting human monoclonal antibody (hMAb) directed against Bordetella pertussis was generated by fusing SP2/HPT heteromyeloma cells with human spleen lymphocytes, after in vitro stimulation for 6 days. The hybridoma was maintained in culture for more than 1 year w …
False colour transmission electron micrograph of the whooping cough bacterium, Bordetella pertussis. The micrograph shows the bacteriums surface covered in fine hairs called pili or frimbriae. Several types of pili have been identified, based on shape & function. Generally, pili cause bacteria to stick together & attach to foreign cells in the body. The fragments around the bacterium are bits of the growth medium. The whooping cough bacteria parasitise only humans, causing a respiratory tract infection characterised by fits of coughing that end in loud inspiratory whoops. It is potentially fatal in infancy. Magnification: X 20,600 at 35mm size. Original is bw print b220/213. - Stock Image B220/0213
False colour transmission electron micrograph (TEM) of a thin section of the whooping cough bacteria, Bordetella pertussis. The whooping cough bacteria parasitise only humans. They cause a respiratory tract infection characterised by fits of coughing that end in loud inspiratory whoops. The infection is usually contracted in childhood and is potentially fatal in infancy. Adults are sometimes affected. The infection damages the epithelium lining the trachea and bronchi, impairing the beat of the cilia that keep the airways clean. Antibiotics are of very limited effect in treatment. Magnification: X 8800 at 35mm size. - Stock Image B220/0221
ICD-10 A37.00 is whooping cough due to bordetella pertussis without pneumonia (A3700). This code is grouped under diagnosis codes for certain infectious and parasitic diseases.
The Sanger Institute has been funded by the Wellcome Trust to sequence the genomes of Bordetella pertussis strain Tohama I, B. parapertussis strain 12822 and B. bronchiseptica strain RB50 in collaboration with Duncan Maskell and Andrew Preston of the Centre for Veterinary Science, Dept. of Clinical Veterinary medicine, The University of Cambridge. The sequences and analysis are described in: Parkhill et al (2003) Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Nature Genetics 35 32-40 (DOI: 10.1038/Ng1227), and have been submitted to EMBL/GenBank with the accession numbers: BX470248 (B. pertussis), BX470249 (B. parapertussis) and BX470250 (B. bronchiseptica). The three sequenced Bordetella strains have been deposited with the ATCC and NCTC under the following accession numbers: Bordetella parapertussis 12822: ATCC BAA-587, NCTC 13253 Bordetella bronchiseptica RB50: ATCC BAA-588, NCTC 13252 Bordetella pertussis Tohama ...
In this study, we have shown that the MLVA is a valuable typing technique to characterize B. pertussis isolates. MLVA is a robust, simple, and portable method which can be used to create strain profiles that are easily electronically exchanged. MLVA has been successfully used to type several different bacterial species and proven to be an excellent method with high resolution, particularly useful for organisms with a low level of sequence diversity (4, 10-12, 16, 18, 19, 27, 28, 31). Although MLVA resulted in high-resolution typing of B. pertussis, the analysis was significantly enhanced after MLVA was combined with sequencing-based analysis of three B. pertussis virulence genes. The latter typing method, designated MAST, also yielded allelic profiles (36). The combined MAST-MLVA profiles were used to perform clustering analyses of the Dutch B. pertussis strains isolated before the introduction of the pertussis vaccine in 1953 and isolates obtained before and after the pertussis epidemics in the ...
Gearing, A.J.; Bird, C.; Wadha, M.; Redhead, K., 1987: The primary and secondary cellular immune responses to whole cell Bordetella pertussis vaccine and its components
The effect of an extract of histamine-sensitizing factor (HSF) of Bordetella pertussis on the immune response of different strains of mice to ovalbumin (OA) was investigated with regard to optimal dose of antigen and adjuvant. It was observed that all strains of mice treated with HSF during immunization with OA demonstrated enhanced production of hemagglutinating antibodies, as compared to animals treated with antigen alone. This enhancement was generally not as great as that demonstrated when Al(OH)3 was the adjuvant. HSF also stimulated a reaginic antibody response (IgE) to OA, but not in all strains of mice. In reagin responders optimal responses were observed with high doses of both antigen and adjuvant, whereas low doses of both produced little or no response. Maximal reagin production occurred usually 14-28 days after immunization and persisted for long periods of time. An anamnestic reagin response was elicited upon secondary immunization with antigen alone, not only in mice immunized ...
Looking for online definition of Bordet-Gengou phenomenon in the Medical Dictionary? Bordet-Gengou phenomenon explanation free. What is Bordet-Gengou phenomenon? Meaning of Bordet-Gengou phenomenon medical term. What does Bordet-Gengou phenomenon mean?
Adenylate cyclase toxin (CyaA) from Bordetella pertussis can subvert host immune responses allowing bacterial colonization. Here we have examined its adjuvant and immunomodulatory properties and the possible contribution of lipopolysaccharide (LPS), known to be present in purified CyaA preparations. CyaA enhanced antigen-specific interleukin-5 (IL-5) and IL-10 production and immunoglobulin G1 antibodies to coadministered antigen in vivo. Antigen-specific CD4+-T-cell clones generated from mice immunized with antigen and CyaA had cytokine profiles characteristic of Th2 or type 1 regulatory T (Tr1) cells. Since innate immune cells direct the induction of T-cell subtypes, we examined the influence of CyaA on activation of dendritic cells (DC) and macrophages. CyaA significantly augmented LPS-induced IL-6 and IL-10 and inhibited LPS-driven tumor necrosis factor alpha and IL-12p70 production from bone marrow-derived DC and macrophages. CyaA also enhanced cell surface expression of CD80, CD86, and ...
Pertussis Vaccine: A suspension of killed Bordetella pertussis organisms, used for immunization against pertussis (WHOOPING COUGH). It is generally used in a mixture with diphtheria and tetanus toxoids (DTP). There is an acellular pertussis vaccine prepared from the purified antigenic components of Bordetella pertussis, which causes fewer adverse reactions than whole-cell vaccine and, like the whole-cell vaccine, is generally used in a mixture with diphtheria and tetanus toxoids. (From Dorland, 28th ed)
FIG 6 Biofilm dispersal by matrix-dissolving agents. Ninety-six-hour biofilms were treated with pronase E in Tris buffer (A), with 40 mM sodium metaperiodate (NaIO4) in H2O (B), and with DNase I in reaction buffer (C) for 2 h at 37°C (filled bars). Biofilms were treated with the respective reaction buffers as controls (open bars). Biofilm reduction is presented as a percentage of the value for the respective strain incubated with buffer only. Average values are shown from one representative assay of three independent replicates, with their respective standard deviations. Significance was assessed by two-way ANOVA. *, P ,0.05; **, P ,0.01; ***, P ,0.001. ...
Since their introduction in the 1940s and 1950s, pertussis vaccines (mostly in combination with diphtheria and tetanus toxoids as diphtheria, tetanus, and pertussis vaccines) have been very efficient in reducing pertussis mortality and morbidity in infants and young children. WHO estimates suggest that between 1999 and 2014, more than 100 000 infant deaths could have been averted mainly by increased coverage of pertussis vaccination.1 Pertussis vaccines come in two varieties: one is made of whole-cell killed Bordetella pertussis cells, consequently called whole-cell pertussis vaccine, and the other is made from one to five purified and partly chemically inactivated bacterial virulence factors, consequently called acellular pertussis vaccine. ...
The adenylate cyclase toxin (AC toxin) is necessary for disease caused by Bordetella pertussis, which has reemerged in the United States over the last two decad...
Despite an increased proportion of Bordetella pertussis isolates lacking pertactin, vaccine effectiveness (VE) is still high in Vermont for the five-dose diphtheria, tetanus, and acellular pertussis vaccine (DTaP) series and the tetanus, diphtheria, and acellular pertussis vaccine (Tdap).
Introduction The routine use of the whole-cell pertussis vaccine has led to a significant reduction in the incidence of the disease in various countries around the world, with a reduction in morbidity and mortality. However, infants up to six months who did not receive the basic vaccination scheme remain susceptible and, when infected by Bordetella pertussis, may present atypical symptoms when compared with older children.1. Over the past few years there have been several reports concerning the severity of pertussis in infants, such as the nine cases reported in the United Kingdom by Smith & Vyas,1 of which six led to death. Severe complications were observed, such as apnea, seizures, respiratory insufficiency, arterial hypotension, pulmonary hypertension, pneumothorax, and secondary bacterial infections.. More recently, another study conducted in the United Kingdom showed that among the 142 infants under five months of age who were hospitalized with a clinical condition of severe respiratory ...
Ca2 Influx and Tyrosine Kinases Trigger Bordetella Adenylate Cyclase Toxin ACT Endocytosis. Cell Physiology and Expression of the CD11b-CD18 Integrin Major Determinants of the Entry Route. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
Pertussis, whooping cough, caused by the gram negative pleomorphic bacillus, Bordetella pertussis, is a highly contagious, potentially life-threatening respiratory illness that has re-emerged in the United States (US) as a cause of morbidity and mortality in infants less than 6 months of age as well as morbidity in adolescents and adults. Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed (Tdap) immunization of women in the third trimester of pregnancy represents an opportunity to protect the vulnerable very young infants through passively acquired maternal pertussis specific antibodies. Tdap vaccine is being evaluated for this purpose since there is no monovalent acellular pertussis (aP) vaccine available in the U.S. This is a multi-site, randomized, double masked, cross-over study in 48 healthy pregnant women, 18-45 years of age who will be randomized (2:1) into two groups. One group will receive a single dose of Tdap vaccine at 30-32 weeks of gestation and a ...
HIGASHI, Hisako G. et al. Acellular and low pertussis vaccines: adverse events and the role of mutations. Rev. Inst. Med. trop. S. Paulo [online]. 2009, vol.51, n.3, pp.131-134. ISSN 1678-9946. http://dx.doi.org/10.1590/S0036-46652009000300002.. Objective: to discuss the current PAHO recommendation that does not support the substitution of traditional cellular DTP vaccine by acellular DTP, and the role of mutations, in humans, as the main cause of rare adverse events, such as epileptic-like convulsions, triggered by pertussis vaccine. Data review: the main components related to toxic effects of cellular pertussis vaccines are the lipopolysaccharide of bacterial cell wall and pertussis toxin. The removal of part of lipopolysaccharide layer has allowed the creation of a safer cellular pertussis vaccine, with costs comparable to the traditional cellular vaccine, and which may be a substitute for the acellular vaccine. Conclusion: The new methodology introduced by Instituto Butantan allows for the ...
13) The preventive measure for Bordetella pertussis infection is the vaccination method, the pertussis vaccine is usually administered in combination with toxoids of Diphtheria and tetanus (DTaP). The pertussis vaccine is primarily important for children, preteens, pregnant women, and adults who have never received it, what doses of this vaccine are recommended for children under six years ...
Pertussis, also known as whooping cough, is an extremely contagious respiratory tract infection caused by the bacteria Bordetella pertussis.
Pertussis, or whooping cough, is a highly infectious, nationally notifiable* respiratory disease associated with prolonged cough illness and paroxysms of coughing, inspiratory whoop, or posttussive vomiting. Reported pertussis cases have tripled in the United States since 2001, with 25,616 probable or confirmed cases reported in 2005 (Figure 1). This increase has been attributed to increased circulation of Bordetella pertussis, waning vaccine-induced immunity among adults and adolescents, heightened awareness of pertussis among health-care providers, increased public health reporting, and increased use of polymerase chain reaction (PCR) testing for diagnosis (1). To minimize the spread of pertussis, control measures must be implemented early in the course of illness when the risk for transmission is highest. However, diagnosis of pertussis is complicated by nonspecific signs and symptoms, particularly in the early catarrhal stage of disease. In addition, the lack of rapid, sensitive, and ...
Bordetella pertussis and Bordetella parapertussis are the causal agents of whooping cough in humans. They produce diverse virulence factors, including adenylate cyclase-hemolysin (AC-Hly), a secreted toxin of the repeat in toxins (RTX) family with cyclase, pore-forming, and hemolytic activities. Post-translational modifications (PTMs) are essential for the biological activities of the toxin produced by B. pertussis. In this study, we compared AC-Hly toxins from various clinical isolates of B. pertussis and B. parapertussis, focusing on (i) the genomic sequences of cyaA genes, (ii) the PTMs of partially purified AC-Hly, and (iii) the cytotoxic activity of the various AC-Hly toxins. The genes encoding the AC-Hly toxins of B. pertussis and B. parapertussis displayed very limited polymorphism in each species. Most of the sequence differences between the two species were found in the C-terminal part of the protein. Both toxins harbored PTMs, mostly corresponding to palmitoylations of the lysine 860 residue
Conventional pertussis vaccine prepared from killed whole cell B. pertussis organisms has been in widespread use since the early 1950s. Despite marked reductions in the incidence of pertussis, the use of the vaccine has caused concern because of questions of significant adverse reactions. Whooping cough is not notifiable in South Africa, and there is consequently a paucity of hard data on efficacy; in addition few cases are proven. Incidence, prevalence, severity and transmission of the disease hence remain a matter of conjecture. In order to provide background information and determine baseline data for undertaking further studies, available clinical and epidemiological data on whooping cough (pertussis) in South Africa was collated. It was intended to compare the pattern of disease seen in this country with that known in other parts of the world. Clinical and epidemiological findings from 1525 whooping cough admissions (diagnosed on the basis of clinical criteria) obtained from 6 major ...
PERTUSSIS (WHOOPING COUGH) If your child has had or develops any of the symptoms listed below, please contact your childs medical provider. Pertussis is a vaccine-preventable disease. However, even children who have been immunized against pertussis are susceptible to infection. Pertussis is most severe in the first year of life, particularly for pre-term infants.. School policy excludes children from school until antibiotic treatment has started. In the case of pertussis, 5 days of antibiotic therapy must be completed before the child may return to school. The child should be feeling well and the cough should be manageable prior to return to school. The full course of antibiotics must be completed to prevent relapse. If antibiotics are not given or not completed, the child may be excluded for 21 days from the onset of the cough. A note from the physician may be requested for return to school. CAUSATIVE AGENT: A bacterium, Bordetella pertussis.. SIGNS AND SYMPTOMS: Symptoms usually start with a ...
Pertussis, also known as whooping cough is a serious respiratory illness. It is an infection that often mimics a common cold in the beginning, but can progress quickly, especially in young infants and children. Pertussis is also known as whooping cough. This is because patients often have violent, rapid coughing fits, leaving them to loudly inhale as they try to refill their lungs with air. View more information about Pertussis.. Pertussis is very contagious and spreads rapidly, usually before a patients cough even develops. A vaccine is available against pertussis. Children receive the vaccine in their normal childhood series of Diptheria, Tetanus, Acellular Pertussis (DTAP) shots, but are not fully protected until age five. An adolescent booster is due at age 11 to 12, before a student enters 7th grade. Adults often pass the pertussis infection on to their children, since their immunity has waned from their own childhood immunizations.. A one-time booster of the pertussis vaccine (given in ...
As of July 14, 2015, whooping cough cases in Clark County, Washington have increased eleven-fold, resulting in health officials announcing that outbreak levels have been reached [1]. Thus far in 2015, Clark County has reported 240 cases of whooping cough, leaving the county on track to mirror its whooping cough outbreak of 2012 [2]. In 2012, an estimated 5,000 individuals fell ill to the disease across Washington State, and this years statewide totals have already surpassed 860 cases [2].. About Whooping Cough. Whooping cough, also known as pertussis, is a highly contagious respiratory illness [3]. Caused by the bacteria Bordetella pertussis, the disease is transmitted person-to-person through coughing and sneezing and close contact with others [3]. Infants are at greatest risk of whooping cough infection, as they are unable to receive the vaccine until at least six months old [6].. Whooping cough infection progresses through three stages: catarrhal stage, paroxysmal stage, and convalescent ...
23 August 2016. Taranaki DHB confirmed today that two children aged less than 6 months old have developed whooping cough and a total of 37 people have been notified with the disease in Taranaki, so far this year. Most cases are in older people and the average age being 27 years old.. Dr Jonathan Jarman said, Whooping Cough is a frightening disease, particularly for babies and young children who might go blue or stop breathing during coughing attacks and many need to be hospitalised.. Whooping Cough can be life-threatening as complications are highest in this very young age group. Also, children who are unimmunised are at especially high risk of infection, he added.. Whooping cough (or pertussis) is a highly contagious illness that is caused by a bacterium (Bordetella pertussis). It is spread by an infected person through droplets produced during coughing or sneezing, which is why it is important to keep babies away from people with coughs and to avoid coughing on babies.. Symptoms start with ...
Looking for Bordetella? Find out information about Bordetella. A genus of gram-negative bacteria which are coccobacilli and obligate aerobes, and fail to ferment carbohydrates. These bacteria are respiratory pathogens.... Explanation of Bordetella
Compliance Statement A: For laboratory developed tests using a manufacturer labeled ASR as the reagent providing the specificity of the assay. Analyte Specific Reagent. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, the FDA has determined that such clearance or approval is not necessary ...
Dr Rizwan Uppal, the founder of IDC, believed that proper and timely diagnosis is the key to successful treatment. An all under one roof diagnostic service with the name of Islamabad Diagnostic Center (IDC) Pvt. Ltd was established in the beautiful City of Islamabad more than a decade ago.. This brain child of Dr Rizwan was not possible without the support of his two brothers and Executive directors, Dr Rehan Uppal and Dr Imran Uppal. Since the day of inception, Dr Rehan has been a great assistance and immense help in IDC progress and evolution. IDCs main strength lies in use of state of the art technology, in the hands of qualified and experienced team of doctors and technologist on 24/7 basis. There is still no such setup of equivalent scale and quality in Pakistan.. IDC is one facility where both laboratory and Radiology services. The widest spectrum of in house laboratory tests and imaging investigations are available nowhere, other than at IDC. To further widen the services of rare but ...
Pertussis (whooping cough) is a respiratory tract infection characterized by a paroxysmal cough. The most common causative organism is Bordetella pertussis (see the image below), though Bordetella parapertussis has also been associated with this condition in humans.
The push for family members and young children to rush and get their DTaP shot is certainly unwarranted when one looks at the many well-documented cases of vaccine failure in communities that experienced record numbers of whooping cough cases. In 1996 there was a statewide outbreak of pertussis in Vermont where vaccination rates were among the highest in the country and yet 97 percent of affected children 19-35 months of age had received the recommended number of vaccines. [3] More recently, The Star-Ledger reported on February 11, 2009 of a pertussis outbreak in 21 fully vaccinated children in Hunterdon county, New Jersey.[4] Closer to home, in Toronto, Ontario, from October 2005 to March 2006, a laboratory-confirmed outbreak of pertussis occurred in fully-vaccinated preschool children.[5] Even the British Medical Journal reported on a study revealing that 55 of the 64 children who presented seriological evidence of a recent Bordetella pertussis infection had been fully vaccinated.[6 ...
© 2017 American College of Chest Physicians Background Pertussis (whooping cough) is a highly infective cause of cough that causes significant morbidity and mortality. Existing case definitions include paroxysmal cough, whooping, and posttussive vomiting, but diagnosis can be difficult. We determined the diagnostic accuracy of clinical characteristics of pertussis-associated cough. Methods We systematically searched CINAHL, Embase, Medline, and SCI-EXPANDED/CPCI-S up to June 2016. Eligible studies compared clinical characteristics in those positive and negative for Bordetella pertussis infection, confirmed by laboratory investigations. Two authors independently completed screening, data extraction, and quality and bias assessments. For each characteristic, RevMan was used to produce descriptive forest plots. The bivariate meta-analysis method was used to generate pooled estimates of sensitivity and specificity. Results Of 1,969 identified papers, 53 were included. Forty-one clinical characteristics
BACKGROUND: Few data exist describing pertussis epidemiology among infants and children in low- and middle-income countries to guide preventive strategies. METHODS: Children 1-59 months of age hospitalized with World Health Organization-defined severe or very severe pneumonia in 7 African and Asian countries and similarly aged community controls were enrolled in the Pneumonia Etiology Research for Child Health study. They underwent a standardized clinical evaluation and provided nasopharyngeal and oropharyngeal swabs and induced sputum (cases only) for Bordetella pertussis polymerase chain reaction. Risk factors and pertussis-associated clinical findings were identified. RESULTS: Bordetella pertussis was detected in 53 of 4200 (1.3%) cases and 11 of 5196 (0.2%) controls. In the age stratum 1-5 months, 40 (2.3% of 1721) cases were positive, all from African sites, as were 8 (0.5% of 1617) controls. Pertussis-positive African cases 1-5 months old, compared to controls, were more often human
In addition, if the trends continue through the end of this year, which they are likely to do, this will be the highest incidence of pertussis in almost 50 years. These numbers are not in question, but there is some discussion about what, exactly, is causing it.. The tempting conclusion is that pertussis is making its way back into the population due largely to vaccine refusal and anti-vaccine propaganda. However, there is yet no data to support that conclusion. It may or may not be the case - we will know once a more thorough analysis is done of the individual cases of pertussis. And in any case, there are many factors at work.. First, pertussis has a natural tendency to cycle every 5 years or so, and this year is the peak of the cycle. This is certainly a significant part of the increase this year, regardless of other contributors.. In addition, the lack of vaccine-induced immunity is also playing a role, but not necessarily from vaccine refusal. Pertussis is a very contagious illness, partly ...
Bordetella Vaccines - Bordetella vaccines will ensure your pet doesnt come down with kennel cough. Learn more about bordetella vaccines and treatments.
Definition of Bordet-Gengou phenomenon. Provided by Stedmans medical dictionary and Drugs.com. Includes medical terms and definitions.
Atack JM, Srikhanta YN, Fox KL, Jurcisek JA, Clark TA, Boitano M, Power PM, Jen FE-C, McEwan AG, Grimmond SM, Smith AL, Barenkamp SJ, Korlach J, Bakaletz LO, Jennings MP. A biphasic epigenetic switch controls immunoevasion, virulence and niche adaptation in nontypeable Haemophilus influenzae. Nat Commun. (January 0.): -.. Ompremcak LB, Rheins MS.. Scanning electron microscopy of mouse ciliated oviduct and tracheal epithelium infected in vitro with Bordetella pertussis. Can J Microbiol. Vol. 29, (January 1982.): 415-420.. Bakaletz LO, Rheins MS.. A whole-organ perfusion model of Bordetella pertussis adherence to mouse tracheal epithelium. In Vitro Cell Dev Biol. Vol. 21, no. 6. (January 1985.): 314-320.. Bakaletz LO, DeMaria TF, Lim DJ.. Effect of preopsonization on phagocytosis of Haemophilus influenzae. Arch Otolaryngol. Vol. 113, no. 5. (January 1987.): 526-529.. Lim DJ, DeMaria TF, Bakaletz LO.. Functional morphology of the tubotympanum related to otitis media: a review. Am J Otol. ...
PubMed Central Canada (PMC Canada) provides free access to a stable and permanent online digital archive of full-text, peer-reviewed health and life sciences research publications. It builds on PubMed Central (PMC), the U.S. National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature and is a member of the broader PMC International (PMCI) network of e-repositories.
PubMed Central Canada (PMC Canada) provides free access to a stable and permanent online digital archive of full-text, peer-reviewed health and life sciences research publications. It builds on PubMed Central (PMC), the U.S. National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature and is a member of the broader PMC International (PMCI) network of e-repositories.
기관지염(氣管支炎, bronchitis)은 폐의 기관지에 생기는 염증이다.[1] 증상으로는 가래, 천명, 호흡 곤란, 가슴의 불편함 등이 있다.[1] 기관지염은 급성 및 만성 두 종류로 분류된다.[1] 급성 기관지염은 기침 감기로도 알려져 있다.[1] 급성 기관지염은 보통 3 주 정도 지속적으로 기침을 한다.[2] 원인의 90 % 이상이 바이러스 감염이다.[2] 이 바이러스는 기침을 통해, 혹은 직접적인 접촉을 통해 공중에 퍼질 수 있다.[1] 흡연, 먼지 및 기타 대기 오염에 대한 노출이 위험 요인이다.[1] 폐렴미코플라스마(Mycoplasma pneumoniae) 나 백일해균(Bordetella pertussis)과 같은 박테리아나 고농도의 대기 오염에 의한 경우도 소량 존재한다.[2][3]급성 기관지염의 치료에는 일반적으로 휴식, paracetamol (acetaminophen) 및 NSAIDs가 발열에 도움이 된다.[4][5] 만성 기관지염은 적어도 2 년 동안, 1 년에 3 ...
Adequately sensitive and specific methods to diagnose pertussis in adolescents and adults are not widely available. Currently, no Food and Drug Administration approved diagnostic assays are available for the serodiagnosis of Bordetella pertussis. Since concentrations of B. pertussis-specific antibodies tend to be high during the later-phases of disease, a simple, rapid, easily transferable serodiagnostic test was developed. This paper describes test development, initial evaluation of a prototype kit enzyme-linked immunosorbent assay (ELISA) in an inter-laboratory collaborative study, and the analytical validation. The data presented here demonstrate that the kit met all pre-specified criteria for precision, linearity, and accuracy for samples with anti-pertussis toxin (PT) immunoglobulin G (IgG) antibody concentrations in the range of 50 to 150 ELISA units (EU)/mL, the range believed to be most relevant for serodiagnosis. The assay met the precision and linearity criteria for a wider range, ...
Grandmother is portrayed as the big bad wolf in a whooping cough vaccine PSA.,br /, ,br /, A killer infectious disease called Pertussis is a bacterial infection that causes whooping cough. Vaccines had brought the numbers of cases down dramatically, but now theyre on the rise again and Texas Biomed animals and scientists are involved in the search for something better to treat this health problem that kills more than a hundred thousand infants a year.,br /, ,br /, Pertussis has seen an alarming resurgence in the last decade. Thats surprising, given that a vaccine for this infectious disease has existed since the 1930s. The original vaccine, made with whole-cell killed Bordetella pertussis bacteria, was very effective but associated with some adverse events. A newer acellular pertussis vaccine with fewer adverse events was approved by the FDA in 1997. Recent epidemiological studies have found, however, that the immunity conferred by the new vaccine wears out during adolescence. Thats a ...
The abilities of cysteine-containing compounds to support growth of and influence pertussis toxin transcription, assembly, and secretion were examined. source of cysteine; however, in the absence of reduced glutathione, pertussis toxin was not efficiently secreted. Addition of the reducing agent dithiothreitol was unable to compensate for the lack of reduced glutathione and did not promote secretion of pertussis toxin. These results suggest that reduced glutathione does not affect the accumulation of assembled active pertussis toxin in the periplasm but plays a role in efficient pertussis toxin secretion by the bacterium. Pertussis toxin is a major virulence factor of heat-labile toxin, and Shiga toxin. Pertussis toxin has the most complex structure of any bacterial toxin (18, 20, 24). It is assembled from six subunits encoded by five genes, to encodes the structural gene for the A-subunit, which is an ADP-ribosyltransferase. S1 modifies mammalian G-proteins, which play a critical role in ...
Before Canadas public pertussis vaccine program, incidence of the disease averaged 156 cases per 100 000 people. In contrast, with a vaccination program, the number of new cases ranged from 2 per 100 000 in 2011 to 13.9 in 2012. Most cases are in under-immunized populations. The current whooping cough vaccine (an acellular vaccine) has been used in Canada since 1997 and is also used in the rest of North America, Australia, New Zealand and much of Europe. The whole-cell vaccine was discontinued in North America because of adverse reactions in children, which included soreness at the injection site and fevers. The current study analyzed public health laboratory data linked with population-level vaccination data for a total of 5867 people born between 1992 and 2013, with 486 individuals testing positive for pertussis and the remaining 5381 testing negative. The researchers found that immunity was high during the first three years after vaccination but there was little protection after seven ...
Previous research in several countries has shown that Bordetella pertussis (whooping cough) infection is an endemic disease among adolescents and adults. Data also shows that neither infection nor immunisation results in lifelong immunity. Yet general practitioners in the UK seldom diagnose or even consider pertussis in older children. It is perceived as a disease of very young children who have not been immunised and who have classic features such as whoop ...
As a pediatric infectious disease specialist, I find it troubling that this study may be used as an excuse not to vaccinate parents and other contacts of young infants. First, the findings do not necessarily apply to areas experiencing high rates of pertussis outbreaks. The report also does not consider communities with a large Hispanic population. When compared with other ethnicities in the United States, Hispanic infants are known to have higher rates of infection and death from pertussis. This is a critical point when looking at a state like Texas, where nearly 40 percent of the population is Hispanic. Since 2000, 34 Texas babies have died from pertussis. The Centers for Disease Control and Prevention recognize that cocooning is needed because even if infants receive antibodies from their mother, these antibodies fade away before the infant has had three doses of pertussis vaccine, given at 2, 4, and 6 months of age. Cocooning is also needed to protect infants born prematurely before the ...
LUBBOCK, TX (KCBD) - The City of Lubbock Health Department would like to notify citizens and clinicians of an increase in Pertussis cases this spring. There have been 22 reported cases in Lubbock County so far in 2010. There were 29 total reported cases of Pertussis in 2009.. Pertussis cases generally increase in the spring and fall months. Pertussis, which is also known as Whooping Cough, is spread by infected persons coughing or sneezing while in close contact with others, who then breathe in the Pertussis bacteria. Many infants who get pertussis are infected by older siblings or parents who might not even know they have the disease.. Pertussis can cause serious illness in children and adults. The disease starts like the common cold, with runny nose or congestion, sneezing, and sometimes mild cough or fever. The cough worsens, becoming severe after 1-2 weeks. Children with the disease cough violently and rapidly, over and over, until the air is gone from their lungs and theyre forced to ...
The Department of Public Health and Social Services (DPHSS) received a laboratory confirmed case of Pertussis (whooping cough) in a 7-month-old child. Epidemiologic investigation of the case to determine possible source of exposure has been initiated.. Pertussis is a highly contagious bacterial disease of the respiratory tract caused by Bordetella Pertussis. Unimmunized or incompletely immunized young infants are particularly vulnerable. It is primarily spread by direct contact with discharge from the nose and throat of infected individuals. It is essential that children receive all their vaccinations on time to prevent this disease.. The DPHSS continues to encourage parents to protect their infants and young children by minimizing exposure (close contact) to persons who have cold symptoms or cough illness. In addition, it is essential that children receive all their shots on time to prevent and control this disease. All physicians are advised to routinely check the immunization status of their ...
Whooping Cough is an acute infection of the respiratory tract, seen only in children. It is typically a prolonged illness with an average duration of 6-8 weeks. The incubation period is 7-10 days. Anyone can get whooping cough, but the health effects are usually much worse for children less than a year old. In Canada, whooping cough now kills one to three infants per year, usually those who are unvaccinated, or under-vaccinated. With proper care, most teenagers and adults recover from whooping cough without complications. Whooping cough is more serious in children, especially infants younger than 6 months of age. Whooping cough - known medically as pertussis -is a highly contagious respiratory tract infection. Pertussis, also called whooping cough, is caused by Bordetella pertussis bacteria and is extremely contagious. Before a vaccine was available, pertussis killed 5,000 to 10,000 people in the United States each year. In the more advanced stages, its marked by the symptom that gives the ...
In the last week, we have seen a couple of little ones show up with confirmed cases of whooping cough.. Whooping cough, or pertussis, is an infection of the respiratory tract caused by the bordetella pertussis bacteria. It starts out looking like the common cold-runny nose, fever, mild cough. This is then followed by severe coughing fits, sometimes with the characteristic whoop sound at the end of the fit. These coughing fits can go on for 10 weeks, giving it the nickname the 100-day cough.. You can hear the sounds of pertussis here.. But…I thought we had vaccines for pertussis?. Whooping cough is actually the second most common infectious childhood disease in Canada, after influenza. Its endemic, meaning its always around, but it usually doesnt show itself much-just in minor periodic outbreaks.. This isnt unusual-the vaccine isnt perfect. Its estimated to have about an 80-85% effectiveness after three doses, and that effectiveness wears off over time. As a result, whooping cough ...
16: Pertussis Parkhill J, et al. (2003). "Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella ... Nieves DJ, Heininger U (2016). "Bordetella pertussis". Bordetella pertussis. Microbiology Spectrum. Vol. 4. pp. 311-339. doi: ... Bordetella pertussis is a Gram-negative, aerobic, pathogenic, encapsulated coccobacillus of the genus Bordetella, and the ... "Bordetella pertussis epidemiology and evolution in the light of pertussis resurgence". Infection, Genetics and Evolution. 40: ...
Bordetella pertussis 1. She was a full professor of biomedicine at Mucosal Immunology and Vaccine Center in Gothenburg. ...
... is an adenylate cyclase produced by Bordetella pertussis. Kessin RH, Franke J (April 1986). " ... Ladant D, Brezin C, Alonso JM, Crenon I, Guiso N (December 1986). "Bordetella pertussis adenylate cyclase. Purification, ... "Secreted adenylate cyclase of Bordetella pertussis: calmodulin requirements and partial purification of two forms". J. ...
In Bordetella pertussis, the infectious agent in childhood whooping cough, filamentous haemagglutinin (FHA) is a surface- ... "Filamentous hemagglutinin of Bordetella pertussis. A bacterial adhesin formed as a 50-nm monomeric rigid rod based on a 19- ... "Beta-helix model for the filamentous haemagglutinin adhesin of Bordetella pertussis and related bacterial secretory proteins". ... Inatsuka CS, Julio SM, Cotter PA (December 2005). "Bordetella filamentous hemagglutinin plays a critical role in ...
Diseases such as pertussis (or whooping cough) are caused by the bacteria Bordetella pertussis. This bacteria is marked by a ... Yeh, Sylvia H.; Mink, ChrisAnna M. (2012). "Bordetella pertussis and Pertussis (Whooping Cough)". Netter's Infectious Diseases ... The pertussis toxin is a protein exotoxin that binds to cell receptors by two dimers and reacts with different cell types such ... PCR is an important testing tool that can detect sequences within the gene for the pertussis toxin. Because PCR has a high ...
2003). "Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella ... and Clinical Manifestations of Respiratory Infections Due to Bordetella pertussis and Other Bordetella Subspecies". Clinical ... 1991). "Effects of Bordetella pertussis infection on human respiratory epithelium in vivo and in vitro". Infection and Immunity ... Luker, K. E.; Collier, J. L.; Kolodziej, E. W.; Marshall, G. R.; Goldman, W. E. (1993). "Bordetella pertussis Tracheal ...
... (PT) is a protein-based AB5-type exotoxin produced by the bacterium Bordetella pertussis, which causes whooping ... Carbonetti NH (2010). "Pertussis toxin and adenylate cyclase toxin: key virulence factors of Bordetella pertussis and cell ... pertussis produces PT and the other species do not. Bordetella parapertussis shows the most similarity to B. pertussis and was ... "Bordetella pertussis population dynamics and phylogeny in Japan after adoption of acellular pertussis vaccines". Microbial ...
Corynebacterium diphtheriae and Bordetella pertussis. ubiquitination and SUMOylation Various full-length, folded proteins can ...
"Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal ... "Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines". Expert Review of Vaccines. 13 ... Kallonen, Teemu; He, Qiushui (2009-07-01). "Bordetella pertussis strain variation and evolution postvaccination". Expert Review ... "Pertactin negative Bordetella pertussis demonstrates higher fitness under vaccine selection pressure in a mixed infection model ...
Pertussis is caused by the bacterium Bordetella pertussis. It is spread easily through the coughs and sneezes of an infected ... Pertussis is caused by the bacterium Bordetella pertussis. It is an airborne disease (through droplets) that spreads easily ... Pertussis infection in these persons may be asymptomatic, or present as illness ranging from a mild cough to classic pertussis ... The pertussis vaccine became available in the 1940s. The classic symptoms of pertussis are a paroxysmal cough, inspiratory ...
It is often seen in conjunction with Bordetella pertussis infections (whooping cough), although not always. Weyant, Robbin S.; ... Bordetella holmesii is a Gram-negative, rod-shaped bacterium of the genus Bordetella. It was named in recognition of Barry ... "Transmission of Bordetella holmesii during Pertussis Outbreak, Japan". Emerging Infectious Diseases. 18 (7): 1166-1169. doi: ... "Bordetella holmesii DNA is not detected in nasopharyngeal swabs from Finnish and Dutch patients with suspected pertussis". ...
With Jules Bordet he isolated Bordetella pertussis in pure culture in 1906 and declared it as the cause of whooping cough. In ... He researched with Jules Bordet the Bordetella pertussis bacteria. At the age of 22, he obtained his doctorate at the ... The pertussis endotoxin. Etiologie de la coqueluche. Etat actuel de la question, 1909 - Etiology of pertussis. Current status ... Le Microbe de la coqueluche, 1906 - The microbe "pertussis". Note complémentaire sur le microbe de la coqueluche, 1906 - ...
... is a highly immunogenic virulence factor of Bordetella pertussis, the bacterium that causes pertussis. Specifically, it is an ... PRN is purified from Bordetella pertussis and is used for the vaccine production as one of the important components of ... Emsley, P.; Charles, I. G.; Fairweather, N. F.; Isaacs, N. W. (1996). "Structure of Bordetella pertussis virulence factor P.69 ... Emsley P, Charles IG, Fairweather NF, Isaacs NW (May 1996). "Structure of Bordetella pertussis virulence factor P.69 pertactin ...
Bordetella pertussis. Bordetella bronchiseptica and Bordetella parapertussis, also able to cause pertussis-like symptoms, also ... Vaccination against Bordetella pertussis is used in infancy to prevent whooping cough. The recent switch from whole-cell ... Adenylate cyclase toxin is a virulence factor produced by some members of the genus Bordetella. Together with the pertussis ... Adenylate cyclase toxin from Bordetella pertussis is a 1706 amino acid residue long protein. The protein consists of three ...
"Vaccine Development for the Control of Bordetella Pertussis Infections". Infection and Immunity. 86 (6): e00004-18. doi:10.1128 ...
"Interaction of human Tamm-Horsfall glycoprotein with Bordetella pertussis toxin". Microbiology. 148 (Pt 4): 1193-1201. doi: ...
Guiso N. 2009.Bordetella pertussis and pertussis vaccines. Clin. Infect. Dis. 49:1565-1569 "1.C.72 The Pertussis Toxin (PTX) ... Pertussis toxin is secreted by the gram-negative bacterium, Bordetella pertussis. Whooping cough is very contagious and cases ... Carbonetti, N. H. (2010). "Pertussis toxin and adenylate cyclase toxin: Key virulence factors of Bordetella pertussis and cell ... The bacterium Bordetella pertussis was first identified as the cause of whooping cough and isolated by Jules Bordet and Octave ...
"Human Serum Antibody Responses to Bordetella pertussis Infection and Pertussis Vaccination". The Journal of Infectious Diseases ...
... and Clinical Manifestations of Respiratory Infections Due to Bordetella pertussis and Other Bordetella Subspecies". Clin ... pertussis) are also motile. B. pertussis and occasionally B. parapertussis cause pertussis or whooping cough in humans, and ... Due to the fact B. pertussis is only found in humans and shows little genetic variation from the other Bordetella species, it ... The three most common species of Bordetella are B. pertussis, B. parapertussis and B. bronchiseptica. These species are known ...
"The O Antigen Enables Bordetella parapertussis To Avoid Bordetella pertussis-Induced Immunity". Infection and Immunity. 75 (10 ... "Clinical characteristics of illness caused by Bordetella parapertussis compared with illness caused by Bordetella pertussis". ... Bordetella parapertussis is a small Gram-negative bacterium of the genus Bordetella that is adapted to colonise the mammalian ... Pertussis caused by B. parapertussis manifests with similar symptoms to B. pertussis-derived disease, but in general tends to ...
Bordetella pertussis, Haemophilus influenzae), and some respiratory tract and soft-tissue infections. The antimicrobial ... "Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromcyin: a case review and cohort study". Lancet ...
Bordetella pertussis is a Gram-negative coccobacillus responsible for causing whooping cough. Yersinia pestis, the bacterium ...
OCLC 630453151.{{cite book}}: CS1 maint: others (link) "Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde ...
Gordon's work focused on pertussis cultures and virulence of the bacterium Bordetella pertussis. Gordon's analysis of pertussis ... Kendrick to support pertussis research at the Michigan Department of Health's Grand Rapids lab around 1944. In the early 1940s ... and the Grand Rapids Pertussis Trials, 1932-1939". Michigan Historical Review. 33 (1): 59-85. doi:10.1353/mhr.2007.0001. JSTOR ... doctors Pearl Kendrick and Grace Eldering with bacteriological virulence research leading to the creation of the pertussis ...
"CSTE Position Statement 13-ID-15". CDC (NNDSS) Diseases and Conditions - Pertussis / Whooping Cough (Bordetella pertussis) 2014 ...
Skerry C, Goldman WE, Carbonetti NH (February 2019). "Bordetella pertussis and Contributes to Sphingosine-1-Phosphate Receptor ... pneumonia associated with impaired bacterial clearance and more severe pulmonary inflammation following Bordetella pertussis ...
These adenylyl cyclases are toxins secreted by pathogenic bacteria such as Bacillus anthracis, Bordetella pertussis, ... "Structural basis for the interaction of Bordetella pertussis adenylyl cyclase toxin with calmodulin". The EMBO Journal. 24 (18 ...
Pertussis is a highly contagious disease that is caused by the bacteria Bordetella pertussis. The bacteria clings to cilia in ... "Pertussis Causes and Transmission". CDC. CDC. Retrieved 10 April 2014. "Pertussis Signs and Symptoms". CDC. CDC. Retrieved 10 ... Unfortunately, the effectiveness of the Pertussis vaccine is dependent on herd immunity, if pertussis is circulating in the ... Pertussis and Tetanus. The DTaP vaccine is given as a 5-shot series at 2, 4, and 6 months, the fourth between 12 and 15 months ...
"Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica". ...
"The calmodulin-sensitive adenylate cyclase of Bordetella pertussis: cloning and expression in Escherichia coli". Molecular ...
One notable bacterium that produces filamentous haemagglutinin adhesin is Bordetella pertussis, which uses this protein as a ... a multifaceted adhesion produced by virulent Bordetella spp". Molecular Microbiology. 9: 653-60. doi:10.1111/j.1365-2958.1993. ...
"Mannose receptor and macrophage galactose-type lectin are involved in Bordetella pertussis mast cell interaction". Journal of ...
Thoden JB, Holden HM (March 2011). "Biochemical and structural characterization of WlbA from Bordetella pertussis and ...
Viridans group streptococci Aerobic Gram-negative bacteria Bordetella pertussis Legionella pneumophila Pasteurella multocida ...
... killed bacteria of the species Bordetella pertussis, Mycobacterium bovis,[citation needed] toxoids Plant saponins from Quillaja ...
Whooping cough, or pertussis, is a contagious respiratory disease caused by the bacteria Bordetella pertussis. It is fatal in ... "Maternal and Neonatal Tetanus Elimination (MNTE)". "Complications of Whooping Cough (Pertussis) , CDC". April 2021. Cohen, ...
Baylisascaris procyonis Bordetella pertussis (Pertussis or whooping cough) Chlamydia pneumoniae Chlamydia trachomatis ( ... Klement E, Grotto I, Srugo I, Orr N, Gilad J, Cohent D (March 2005). "Pertussis in soldiers, Israel". Emerging Infect. Dis. 11 ...
With Octave Gengou, he isolated Bordetella pertussis in pure culture in 1906 and posited it as the cause of whooping cough. He ... The bacterial genus Bordetella is named after him. The Nobel Prize in Physiology or Medicine was awarded to him in 1919 for his ...
Like Bordetella pertussis, it forms a calmodulin-dependent adenylate cyclase exotoxin known as anthrax edema factor, along with ...
As a result, it enables establishment of Bordetella infection of airway mucosa and promotes immune evasion of B. pertussis, by ... Adenylate cyclase toxin (CyaA) is released from bacterium Bordetella pertussis by the T1SS (Type 1 secretion system) and ... pertussis bacteria that enter into human and murine macrophages by a non-phagocytic mechanism. Pertussis toxin Anthrax toxin ... Sebo P, Osicka R, Masin J (October 2014). "Adenylate cyclase toxin-hemolysin relevance for pertussis vaccines". Expert Review ...
Anaplasmosis Aspergillus BK virus Bordetella pertussis Borrelia miyamotoi Clostridium difficile Cryptococcus gattii ...
... a bacteriocin active against phase I organisms of Bordetella pertussis. H. pertucinogena was originally assigned to the genus ...
Four diseases were responsible for 98% of vaccine-preventable deaths: measles, Haemophilus influenzae serotype b, pertussis, ... Bordetella Canine distemper Canine influenza Canine parvovirus Chlamydia Feline calicivirus Feline distemper Feline leukemia ... pertussis, poliomyelitis, rubella, tetanus, tuberculosis, and yellow fever. The WHO reports licensed vaccines being available ... infection Influenza Japanese encephalitis Malaria Measles Meningococcal disease Monkeypox Mumps Pneumococcal disease Pertussis ...
Bordetella pertussis, Bacillus anthracis, Corynebacterium diphtheriae, Neisseria gonorrhoeae, Chlamydophila pneumoniae, ...
Pertussis toxin (PTx) of Bordetella pertussis, formerly known as lymphocytosis-promoting factor, causes a decrease in the entry ...
Because pertussis is known to be caused by the bacterium Bordetella pertussis, vaccination is effective. A paper co-authored in ... July 2018). "Pertussis Immunisation in Pregnancy Safety (PIPS) Study: A retrospective cohort study of safety outcomes in ... "Pertussis (Whooping Cough)". Centers for Disease Control and Prevention. Archived from the original on 29 December 2021. ... 16 July 2019). "Pertussis Vaccination Failure in the New Zealand Pediatric Population: Study Protocol". Vaccines. 7 (65): 65. ...
... and Bordetella pertussis may help prevent it. The management of rhinitis depends on the underlying cause. For allergic rhinitis ...
Bordetella pertussis strain lacking pertactin and pertussis toxin. Emerg Infect Dis. 2016 Feb;22(2):319-22. ... Genomic Survey of Bordetella pertussis Diversity in the United States, 2000-2013. Emerg Infect Dis. 2019 Apr;25(4):780-783. ... Pertactin-negative Bordetella pertussis strains: Evidence for a possible selective advantage. Clin Infect Dis. 2015 Jan 15;60( ... The history of Bordetella pertussis genome plasticity and conserved rearrangement. J Bacteriol. 2017 Mar 28: 199(8). ...
Laboratory Manual for the diagnosis of whooping cough caused by bordetella pertussis/bordetella parapertussis : update 2014  ... Evaluation of purified monoclonal antibodies to Bordetella pertussis fimbriae type 2 and 3 : study report and proposal to ... evaluation of proposed international standard monoclonal antibodies for serotyping bordetella pertussis fimbrial antigen 2 and ... Pertussis surveillance : a global meeting, Geneva, 16-18 October 2000  World Health Organization (‎World Health ...
IS481-like element IS481 family transposase [Bordetella pertussis]. NCBI Reference Sequence: WP_010930066.1 ...
Bordetella pertussis Toxin PT; and Bordetella pertussis Whole-Cell Antigens have been expressly designed for use as integral ... The Bordetella pertussis FHA; Bordetella pertussis Toxin PT; and Bordetella pertussis Whole-Cell Antigens have been expressly ... The Bordetella pertussis FHA; Bordetella pertussis Toxin PT; and Bordetella pertussis Whole-Cell Antigens have been expressly ... Bordetella pertussis is the causative agent of Pertussis, or "Whooping Cough". In addition, Bordetella pertussis also has the ...
Bordetella pertussis is a Gram-negative human-restricted bacterium that evolved from the broad-range mammalian pathogen, ... The introduction of the pertussis whole-cell vaccination for young children, followed by the introduction of the pertussis ... Bordetella bronchiseptica. It causes whooping cough or pertussis in humans, which is the most prevalent vaccine-preventable ... B. pertussis is relatively monomorphic worldwide, but nevertheless, different countries are facing different epidemiological ...
Analysis of clinical Bordetella pertussis isolates using whole genome sequences reveals novel genomic regions associated with ... Analysis of clinical Bordetella pertussis isolates using whole genome sequences reveals novel genomic regions associated with ... Background: Despite high-levels of vaccination, whooping cough, primarily caused by Bordetella pertussis (BP), has persisted ... Analysis of clinical Bordetella pertussis isolates using whole genome sequences reveals novel genomic regions associated with ...
More Details about Anti-B. pertussis Toxin IgG Related Product. Anti-B. pertussis Toxin IgG. Anti-B. pertussis Toxin IgG is is ... Launch Diagnostics is a licensed reseller and distributor of Bordetella pertussis IgG. Launch Diagnostics is the largest ... an ELISA-based, automated, in-vitro test system for the quantitative determination of IgG antibodies against pertussis toxin in ...
Bordetella pertussis Strain Lacking Pertactin and Pertussis Toxin Cite CITE. Title : Bordetella pertussis Strain Lacking ... A Bordetella pertussis strain lacking 2 acellular vaccine immunogens, pertussis toxin and pertactin, was isolated from an ... Rapid Increase in Pertactin-deficient Bordetella pertussis Isolates, Australia Cite CITE. Title : Rapid Increase in Pertactin- ... Title : Bordetella pertussis, Finland and France Personal Author(s) : Caro, Valérie;Elomaa, Annika;Brun, Delphine;Mertsola, ...
Bordetella pertussis) case definitions; uniform criteria used to define a disease for public health surveillance. ... Pertussis / Whooping Cough (Bordetella pertussis) , Revised May 2, 1997. *Pertussis / Whooping Cough (Bordetella pertussis) , ... Pertussis (Whooping Cough) (Bordetella pertussis) , 2020 Case Definition. *Pertussis / Whooping Cough (Bordetella pertussis) , ... Pertussis / Whooping Cough (Bordetella pertussis) , 1996 Case Definition. *Pertussis / Whooping Cough (Bordetella pertussis) , ...
Contributions of the Hydrophobic Helix 2 of the Bordetella pertussis CyaA-hemolysin to Membrane Permeabilization ... "Contributions of the Hydrophobic Helix 2 of the Bordetella pertussis CyaA-hemolysin to Membrane Permeabilization" , in Protein ...
The Bordetella pertussis toxin (PT) Antibody (IgG), Im Quest lab test contains 1 test with 1 biomarker. ... Bordetella pertussis toxin (PT) Antibody (IgG), Im The Bordetella pertussis toxin (PT) Antibody (IgG), Im test contains 1 test ... Bordetella pertussis toxin (PT) Antibody (IgG), Immunoassay #37295 1 Biomarkers - Average Process Time*: 4 to 5 days ...
A truncated Bordetella pertussis cya gene product was expressed in Escherichia coli and purified by affinity chromatography on ... Isolation and characterization of catalytic and calmodulin-binding domains of Bordetella pertussis adenylate cyclase. Hélène ... Abstract : A truncated Bordetella pertussis cya gene product was expressed in Escherichia coli and purified by affinity ... Isolation and characterization of catalytic and calmodulin-binding domains of Bordetella pertussis adenylate cyclase.. European ...
CDC-recommended first-line tests for pertussis are Bordetella pertussis/parapertussis by PCR (0065080) and/or Bordetella ... pertussis Culture (0060117). In most cases, serology testing is not recommended for the diagnosis of active pertussis infection ... If Bordetella pertussis Antibody, IgG by ELISA is 1.05 IV or greater, then Bordetella pertussis IgG Immunoblot testing will be ... CDC-recommended first-line tests for pertussis are Bordetella pertussis/parapertussis by PCR (0065080) and/or Bordetella ...
Bordetella pertussis infection in Chandigarh. Indian Journal of Medical Research. 1973 May; 61(5): 645-8. ...
Filed Under: How to Parent Tips, The Breeze Tagged With: adult vaccinations, Bordetella pertussis, contagious diseases, ... Whooping Cough is a highly contagious, vaccine-preventable bacterial disease caused by Bordetella pertussis. It lasts for many ... The perception that pertussis is something we dont have to worry about obscures the fact that, despite effective vaccines and ... For many people, pertussis (commonly known as Whooping Cough) is old news-a once-feared disease long controlled by vaccination ...
Pathogenesis and immunity in pertussis / edited by Alastair C. Wardlaw and Roger Parton. by Wardlaw, Alastair C , Parton, Roger ... The immunological basis for immunization series: module 4: pertussis - update 2009. by World Health Organization. ... pertussis - update 2009..Online access: Click here to access online Availability: Items available for loan: WHO HQ (1)Call ...
Dive into the research topics of A qPCR assay for Bordetella pertussis cells that enumerates both live and dead bacteria. ... A qPCR assay for Bordetella pertussis cells that enumerates both live and dead bacteria. ...
Pertussis FHA IgA och IgG samt Pertussis toxin IgA och IgG, utförs alltid tillsammans. ...
Es un análisis para determinar la presencia de anticuerpos contra la Bordetella pertussis en la sangre. La B. pertussis es la ... Anticuerpos contra Bordetella pertussis (en sangre). ¿Esta prueba tiene otros nombres?. Prueba de anticuerpos contra la tos ... Si nunca lo vacunaron contra la tos ferina, el valor normal de anticuerpos contra la B. pertussis es de cero. Si tiene la ... vacuna, es probable que tenga anticuerpos IgG contra la B. pertussis, incluso si no está atravesando una infección activa de ...
Our Testing Menu ,, BORDETELLA PERTUSSIS, A/G/M BORDETELLA PERTUSSIS, A/G/M. *Item #: ZG941 ...
Bordetella pertussis toxin, manufactured by The Native Antigen Company. High quality and minimal lot to lot variation ensures ... Bordetella Pertussis Toxin. $328.60. - $1,267.90. excl. VAT. Purified native pertussis toxin from Bordetella pertussis, in ... BORDETELLA PERTUSSIS TOXIN. Bordetella pertussis toxin has been developed in response to increasing pressure on the IVD ... Bordetella pertussis is grown in batch culture, then the supernatant harvested and concentrated. Several rounds of ...
Bordetella pertussis. Macrolide. Trimethoprim- sulfamethoxazole. Anaerobe (aspiration). Beta-lactam/beta-lactamase inhibitor, ...
Αυτός ο ιστότοπος χρησιμοποιεί cookies για να βελτιώσει την εμπειρία σας ενώ περιηγείστε στον ιστότοπό μας. Από αυτά, τα cookies που κατηγοριοποιούνται ως "απαραίτητα" αποθηκεύονται στο πρόγραμμα περιήγησής σας, καθώς είναι απαραίτητα για τη λειτουργία βασικών λειτουργιών του ιστότοπου. Χρησιμοποιούμε επίσης cookies τρίτων που μας βοηθούν να αναλύσουμε και να κατανοήσουμε το πώς χρησιμοποιείτε αυτόν τον ιστότοπο. Αυτά τα cookies αποθηκεύονται στο πρόγραμμα περιήγησής σας μόνο με τη συγκατάθεσή σας. Έχετε επίσης την επιλογή να εξαιρεθείτε από αυτά τα cookies, ...
Bordetella pertussis; Coqueluche; Humanos; Toxina Pertussis; Fatores de Virulência de Bordetella; Toxina Adenilato Ciclase; ... Pasteurian Contributions to the Study of Bordetella pertussis Toxins. Locht, Camille. Afiliação *Locht C; Univ. Lille, CNRS, ... Pasteurian Contributions to the Study of ,i,Bordetella pertussis,/i, Toxins. ... Bordetella pertussis / Coqueluche Tipo de estudo: Estudo prognóstico / Revisão sistemática Limite: Humanos Idioma: Inglês Ano ...
Pertussis is a highly contagious bacterial disease that causes uncontrollable, violent coughing. The coughing can make it hard ... Pertussis (Bordetella pertussis and Bordetella parapertussis). In: Kliegman RM, St. Geme JW, Blum NJ, Shah SS, Tasker RC, ... Pertussis, or whooping cough, is an upper respiratory infection. It is caused by the Bordetella pertussis bacteria. It is a ... Pertussis should always be considered when vomiting occurs with coughing. In infants, choking spells and long pauses in ...
Bordetella pertussis 1 * Bordetella petrii 1 * Bradyrhizobium sp. 1 * Brucella abortus 1 ...
  • Bordetella pertussis strain lacking pertactin and pertussis toxin. (cdc.gov)
  • In addition, Bordetella pertussis also has the ability to inhibit the function of the host's immune system via pertussis toxin (PT). (labmanager.com)
  • Anti-B. pertussis Toxin IgG is is an ELISA-based, automated, in-vitro test system for the quantitative determination of IgG antibodies against pertussis toxin in human serum or. (launchdiagnostics.com)
  • The Bordetella pertussis toxin (PT) Antibody (IgG), Im test contains 1 test with 1 biomarker. (ultalabtests.com)
  • Pertussis FHA IgA och IgG samt Pertussis toxin IgA och IgG, utförs alltid tillsammans. (regionvastmanland.se)
  • Purified native pertussis toxin from Bordetella pertussis , in lyophilised form for ease of shipping, activity tested in a CHO cluster assay. (thenativeantigencompany.com)
  • Bordetella pertussis toxin has been developed in response to increasing pressure on the IVD industry to supply highly specific, cost-effective antibody capture systems, which are needed for monitoring vaccination programmes. (thenativeantigencompany.com)
  • Our PT-TNL-50 vials are a major seller to academic labs seeking to use pertussis toxin as a research reagent, and are also sold through large worldwide distributors. (thenativeantigencompany.com)
  • Genomic variations are mostly studied in the circulating strains of B. pertussis to know the pathogen adaptation to the vaccine antigens such as pertussis toxin ( ptx ), pertactin ( prn ), fimbriae ( fim ) and filamentous hemagglutinin (FHA) [ 3 ]. (jgenomics.com)
  • Besides identifying B. pertussis as the causative agent of whooping cough , Pasteurians have made several major contributions with respect to the structure-function relationship of the Bordetella lipo- oligosaccharide , adenylyl cyclase toxin and pertussis toxin . (bvsalud.org)
  • Analysis of Bordetella pertussis pertactin and pertussis toxin types from Queensland, Australia, 1999-2003. (cdc.gov)
  • These changes include antigenic divergence with vaccine strains and increased production of pertussis toxin. (cambridge.org)
  • Antigenic divergence will affect both memory recall and the efficacy of antibodies, while higher levels of pertussis toxin may increase suppression of the innate and acquired immune system. (cambridge.org)
  • After purification, filamentous hemagglutinin (FHA) and pertussis toxin (PT) are combined to obtain a 1:1 ratio and are then treated with formaldehyde to inactivate PT. (cdc.gov)
  • A PCR procedure for the detection of Bordetella pertussis in nasopharyngeal aspirates (NPAs) was developed with primers derived from the pertussis toxin promoter region. (microbiologyresearch.org)
  • La B. pertussis es la bacteria que causa la tos ferina. (oumedicine.com)
  • It is caused by the Bordetella pertussis bacteria. (medlineplus.gov)
  • Transmission typically happens when a person with pertussis coughs or sneezes, and another person nearby breathes in the bacteria. (livescience.com)
  • This Gram-stained photomicrograph depicts numbers of Bordetella pertussis bacteria, which is the etiologic pathogen for pertussis, also known as whooping cough. (livescience.com)
  • The term "acellular" means that the vaccine uses pieces of pertussis bacteria (not the whole bacterium cell). (cdc.gov)
  • Hexacima is a vaccine containing active substances derived from diphtheria, tetanus, pertussis and Haemophilus influenzae type b bacteria , the hepatitis B virus, and inactivated polioviruses. (europa.eu)
  • Further, the impact of vaccination needs to be established since more than one strain used in the manufacturing of pertussis vaccines globally. (jgenomics.com)
  • We propose these adaptations of B. pertussis have decreased the period in which pertussis vaccines are effective and thus enhanced the waning of immunity. (cambridge.org)
  • We plead for a more integrated approach to the pertussis problem which includes the characteristics of the vaccines, the B. pertussis populations and the interaction between the two. (cambridge.org)
  • Whole-cell pertussis vaccines in the United States have been and continue to be prepared from suspensions of killed Bordetella pertussis whole bacterial cells. (cdc.gov)
  • Routine vaccination with whole-cell vaccines has been highly effective in reducing the burden of disease and deaths due to pertussis (3). (cdc.gov)
  • these concerns have led to attempts to develop safer pertussis vaccines that have high efficacy. (cdc.gov)
  • Candidate acellular pertussis vaccines, produced by multinational manufacturers, are now available due to advances in the methods of purifying and preparing these components. (cdc.gov)
  • Several clinical trials, which compare relative protective efficacy of primary vaccination utilizing diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccines with that of whole-cell vaccines administered to infants, are in progress or development. (cdc.gov)
  • Household exposure and ecologic studies among Japanese children vaccinated at greater than or equal to 2 years of age, have suggested efficacy of the BIKEN and other acellular pertussis vaccines when combined with diphtheria and tetanus toxoids as DTaP (4-7). (cdc.gov)
  • Protection against pertussis in the very young baby - adult vaccines, pre-partum maternal immunization or neonatal immunization? (escmid.org)
  • Before pertussis vaccines became widely available in the 1940s, about 200,000 children got sick with it each year in the U.S.and about 9,000 died as a result of the infection," the CDC says on its website. (go.com)
  • So, we get vaccines for our dogs against Bordetella . (cdc.gov)
  • We do get vaccines for our dogs against Bordetella . (cdc.gov)
  • The mutation rate of a virus is considerably higher than that of a bacterium, meaning that in this case, in our case, Bordetella pertussis does not evolve that fast except for the antigen genes that are used in the commercial vaccines. (cdc.gov)
  • Infant immunization programmes using pertussis vaccines have been highly successful in preventing severe pertussis in infants all over the world. (who.int)
  • Pertactin-negative Bordetella pertussis strains: Evidence for a possible selective advantage. (cdc.gov)
  • Multiple-locus variable-number tandem repeat analysis of Dutch Bordetella pertussis strains reveals rapid genetic changes with clonal expansion during the late 1990s. (cdc.gov)
  • Sharma NC, Anandan S, Devanga Ragupathi NK, Muthuirulandi Sethuvel DP, Vasudevan K, Kumar D, Gupta SK, Sangal L, Veeraraghavan B. Genetic Diversity of Clinical Bordetella Pertussis ST2 Strains in comparison with Vaccine Reference Strains of India. (jgenomics.com)
  • Current study reports the highly accurate complete genomes of two clinical B. pertussis strains from India for the first time. (jgenomics.com)
  • Complete genome sequencing was performed for two B. pertussis strains using Ion Torrent PGM and Oxford nanopore sequencing method. (jgenomics.com)
  • The two B. pertussis clinical strains exhibited diversity through genome degradation when compared to whole-cell vaccine reference strains of India. (jgenomics.com)
  • The genome information of Indian clinical B. pertussis strains will serve as a baseline data to decipher more information on the genome evolution, virulence factors and their role in pathogenesis for effective vaccine strategies. (jgenomics.com)
  • The comparative genomic analysis would provide high resolution data to study the structural variations in the circulating strains of B. pertussis against vaccine strains. (jgenomics.com)
  • Here we report the comparative genomic analysis of two clinical isolates of B. pertussis from India against the vaccine reference strains 6229, 25525, 134, 509, 10536 and Tohama I. (jgenomics.com)
  • Temporal trends in circulating Bordetella pertussis strains in Australia. (cdc.gov)
  • Comparisons with vaccine strains are included.Results: From 8,176 patients with pertussis clinical signs, 22.9% were confirmed: 523 in 2006, 617 in 2007, and 734 in 2008. (conicet.gov.ar)
  • Moreover, while vaccine strains contain prn1/7 and ptxS1 B/D alleles, local isolates have prn2 and ptxS1A.Conclusions: Pertussis is an important problem for public health in Argentina. (conicet.gov.ar)
  • Delay in vaccine application, and divergence between vaccine strains and local isolates could contribute to the described pertussis epidemiology. (conicet.gov.ar)
  • Cassiday PK, Skoff TH, Jawahir S, Tondella ML. Changes in the predominance of pulsed-field gel electrophoresis profiles of Bordetella pertussis isolates, United States, 2000-2012. (cdc.gov)
  • 2 ). Forty-one potential VNTR loci from the B. pertussis Tohama I genome ( 3 ) were identified and screened on a panel of 18 B. pertussis isolates selected on the time and locality of isolation (Supplementary Table 1). (cdc.gov)
  • pertussis isolates in Japan. (cdc.gov)
  • Disease relevance of brk A In this study, we set up a real- time reverse transcriptase PCR assay to measure the relative amounts of brk A transcripts in 50 Bordetella isolates. (wikigenes.org)
  • Differential In Vitro Expression of the brk A Gene in Bordetella pertussis and Bordetella parapertussis Clinical Isolates. (wikigenes.org)
  • B. pertussis isolates were characterized by pulse filed gel electrophoresis (PFGE) and prn and ptx genotypes. (conicet.gov.ar)
  • Sources of infant pertussis infection in the United States. (cdc.gov)
  • In most cases, serology testing is not recommended for the diagnosis of active pertussis infection. (aruplab.com)
  • IMSEAR at SEARO: Bordetella pertussis infection in Chandigarh. (who.int)
  • Pertussis, or whooping cough, is an upper respiratory infection. (medlineplus.gov)
  • DTaP vaccination , one of the recommended childhood immunizations, protects children against pertussis infection. (medlineplus.gov)
  • Pertussis, caused by Bordetella pertussis, is a highly contagious respiratory infection, characterized by severe episodes of coughing and a prolonged convalescent period when the patient can transmit the disease [ 1 ]. (jgenomics.com)
  • These applications range from the development of novel tools to study protein - protein interactions over the design of novel antigen delivery tools, such as prophylactic or therapeutic vaccine candidates against cancer and viral infection , to the development of a live attenuated nasal pertussis vaccine . (bvsalud.org)
  • Pertussis or whooping cough has persisted and resurged in the face of vaccination and has become one of the most prevalent vaccine-preventable diseases in Western countries with estimated infection frequencies of 1-9% [ Reference Ward 1 - Reference Hallander 4 ]. (cambridge.org)
  • Whooping cough, also known as pertussis, is a bacterial infection of the respiratory tract that causes severe coughing. (livescience.com)
  • After a week or two, pertussis infection delivers its cruel surprise - uncontrollable, violent coughing spells. (cdc.gov)
  • It stopped them from getting influenza which in turn protected them from getting a co-infection of pertussis. (news24.com)
  • ABSTRACT Although pertussis is a vaccine-preventable infection, vaccine-induced immunity is not lifelong and booster doses are recommended according to national disease epidemiology. (who.int)
  • RÉSUMÉ Si la coqueluche est une infection évitable par la vaccination, l'immunité induite par le vaccin ne dure pas toute la vie et des doses de rappel sont recommandées en fonction de l'épidémiologie de la maladie dans le pays. (who.int)
  • There were some severe cases of pertussis among infants caused mainly by B. pertussis and dual Bordetella infection. (who.int)
  • A highly infectious, vaccine-preventable disease lasting many weeks, is caused by infection with Bordetella Pertussis. (who.int)
  • In cases of severe pneumonia and ARDS, can there be a bacterial co-infection, such as bordatella pertussis, that has been vaccinated in childhood but whose antibody titer has declined over the years? (ejmo.org)
  • Bordetella pertussis is a Gram-negative human-restricted bacterium that evolved from the broad-range mammalian pathogen, Bordetella bronchiseptica. (pasteur.fr)
  • Pertussis is a highly contagious disease of the respiratory tract caused by Bordetella pertussis , a bacterium that lives in the mouth, nose, and throat. (jgenomics.com)
  • Whooping cough is caused by the bacterium Bordetella pertussis . (livescience.com)
  • Pertussis is a highly contagious respiratory disease caused by the bacterium Bordetella pertussis . (news24.com)
  • The contagious cough, named for its "whooping" sound, is caused by the bacterium Bordetella pertussis, which is spread through coughs and sneezes. (go.com)
  • Bordetella pertussis is a gram- negative bacterium that is responsible for the highly contagious respiratory disease known as pertussis. (cdc.gov)
  • San Diego, CA - Binding Site's Immunologicals Group is pleased to announce the addition of three (3) new Bordetella pertussis (VZV) antigens to its broad offering of products for in-vitro diagnostic (IVD) manufacturing and research applications. (labmanager.com)
  • All of these Bordetella pertussis antigens exhibit exceptional purity levels as a result of chromatography techniques and demonstrate exceptional lot-to-lot consistencies, while displaying the highest degrees of activity and specificity. (labmanager.com)
  • Chan WF , Maharjan RP , Reeves PR , Sintchenko V , Gilbert GL , Lan R . Rapid and accurate typing of Bordetella pertussis targeting genes encoding acellular vaccine antigens using real time PCR and high resolution melt analysis. (cdc.gov)
  • CDC-recommended first-line tests for pertussis are Bordetella pertussis/parapertussis by PCR ( 0065080 ) and/or Bordetella pertussis Culture ( 0060117 ). (aruplab.com)
  • But pertussis vaccination rate in Texas - about 94 percent - lags behind the national average , according to the U.S. Centers for Disease Control and Prevention. (go.com)
  • Whooping Cough' is a highly contagious, vaccine-preventable bacterial disease caused by Bordetella pertussis. (breezymama.com)
  • Pertussis is a highly contagious bacterial disease that causes uncontrollable, violent coughing. (medlineplus.gov)
  • Whooping cough (pertussis) is a contagious illness. (ahealthyme.com)
  • Pertussis is highly contagious (easy to catch). (cdc.gov)
  • Pertussis is a highly contagious bacterial disease of the respiratory tract caused by Bordetella pertussis . (who.int)
  • 1.05 IV or greater: Positive - IgG antibody to B. pertussis detected, which may indicate a current or recent exposure/immunization to B. pertussis . (aruplab.com)
  • Immunological basis for immunization : module 4: pertussis - update 2009. (who.int)
  • Since 2005, a single dose of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine has been recommended by the Advisory Committee on Immunization Practices (ACIP) for adolescents and adults ( 1 , 2 ). (cdc.gov)
  • Proportion of pertussis cases by age, immunization status, and immunization coverage rate evaluated at the Argentinean National Pertussis Reference Center are reported. (conicet.gov.ar)
  • 3. Kuo SC, Shih SM, Chien LH, Hsiung CA. Collateral benefit from 10 patients with pertussis revealed a macrolide-re- of COVID-19 control measures on influenza activity, sistant mutation, A2047G, in the 23S rRNA. (cdc.gov)
  • Usually these patients with pertussis experience around the second week after the onset of the symptoms a fit of coughing, followed by a high-pitched whoop sound, and hence the name of whooping cough. (cdc.gov)
  • The high circulation rate of Bordetella pertussis poses a threat to infants that have not been (completely) vaccinated and for whom pertussis is a severe, life-threatening, disease. (cambridge.org)
  • Pregnant women are recommended to receive a dose of Tdap during each pregnancy to prevent pertussis in infants too young for routine vaccination (off-label use*) ( 3 ). (cdc.gov)
  • Pertussis, also known as whooping cough, is a respiratory disease that can be fatal, especially for infants. (cdc.gov)
  • Many infants who get pertussis are infected by older siblings, parents or caregivers who might not even know they have the disease Pertussis loves crowded locations to encourage close contact among potential victims and to make its job easier. (cdc.gov)
  • Pertussis is a bully, often causing serious and sometimes life-threatening complications in infants and young children, especially those who are not fully vaccinated. (cdc.gov)
  • In infants younger than 1 year of age who get pertussis, more than half are hospitalized. (cdc.gov)
  • Whooping cough, or pertussis, mainly affects infants and young children. (childrenshospital.org)
  • Texas has already seen two pertussis-related deaths this year - both of them in infants who were too young to be vaccinated, according to the state's department of health. (go.com)
  • During 2010, 27,550 cases of pertussis were reported in the U.S. - the most since 1959. (cdc.gov)
  • 5 According to data on vaccine-preventable diseases collected through the WHO/United Nations Children's Fund (UNICEF) Joint Reporting Form, around 5000 suspected cases of pertussis were reported in syndromic surveillance by health workers in Papua New Guinea in 2010. (who.int)
  • General recommendations on pertussis prevention were issued August 8, 1991, in the ACIP statement on diphtheria, tetanus, and pertussis (1). (cdc.gov)
  • A supplementary statement on the use of diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) was issued February 7, 1992 (2) after the licensure of ACEL-IMUNE (Registered), prepared by Lederle Laboratories. (cdc.gov)
  • Simultaneous vaccination against diphtheria, tetanus, and pertussis during infancy and childhood has been a recommended routine practice in the United States since the late 1940s. (cdc.gov)
  • Repeat doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine at 5- and 10-year intervals are safe and immunogenic. (cdc.gov)
  • Since 2005, a single booster dose of Tdap has been recommended for children and adolescents aged 11-18 years and adults aged 19-64 years ( 1 , 2 ) to increase protection against tetanus, diphtheria, and pertussis. (cdc.gov)
  • The vaccine ammo contains diphtheria (the D), tetanus (the T), and acellular pertussis (the aP). (cdc.gov)
  • This is usually part of the DTaP vaccine (which stands for diphtheria, tetanus, and pertussis). (childrenshospital.org)
  • The Central Province conducted a response vaccination programme providing 65% of children less than five years of age with diphtheria-pertussis-tetanus-HepB-Hib vaccine at a cost of US$ 12.62 per child. (who.int)
  • That same year, 70% of children less than one year of age in Papua New Guinea received three doses of diphtheria-pertussis-tetanus vaccine (DPT). (who.int)
  • 6 In Papua New Guinea, DPT has been provided as diphtheria-pertussis-tetanus-hepatitis B-Haemophillus influenza B (pentavalent) vaccine since 2008. (who.int)
  • A lack of adequate evidence, until recently, to demonstrate the effectiveness of any single preparation has delayed U.S. licensure for any indication of a candidate acellular pertussis vaccine. (cdc.gov)
  • The acellular pertussis vaccine components are purified from Bordetella pertussis by salt precipitation, ultracentrifugation, and ultrafiltration. (cdc.gov)
  • Booster vaccination with an acellular pertussis vaccine should be considered in adolescents and/or adults in our region. (who.int)
  • However, significant changes in B. pertussis populations have been observed after the introduction of vaccinations, suggesting a role for pathogen adaptation in the persistence and resurgence of pertussis. (cambridge.org)
  • On the other hand, when applied to two batches of Bordetella bronchiseptica strain 4650, it highlighted the presence, in one of them, of hitherto unreported hexosamine residues substituting the lipid A phosphate groups, possibly a new camouflage opportunity to escape a host defense system. (jlr.org)
  • But the dog's Bordetella belongs to the species Bordetella bronchiseptica , which is not the same as the one that produces disease in humans. (cdc.gov)
  • If you've been reading the news the past few weeks, you may have heard about the recent outbreak of pertussis that has reached epidemic levels in Washington. (cdc.gov)
  • A large outbreak of pertussis was detected during March 2011 in Goilala, a remote district of the Central Province in Papua New Guinea, characterized by rugged topography with no road access from the provincial headquarters. (who.int)
  • On 30 March 2011, the health workers of Ononge health centre, through the Health Secretary of Catholic Health-Diocese of Berenia, informed the Central Provincial Health Office about a suspected outbreak of pertussis in several villages of the Goilala district. (who.int)
  • A person with pertussis will infect almost everyone in their household if those people aren't vaccinated. (cdc.gov)
  • Pertussis is primarily an "air attacker," flying through the air looking for its next victim, when an infected person coughs or sneezes. (cdc.gov)
  • Anyone can get pertussis, which is spread from person to person when an infected person coughs or sneezes. (news24.com)
  • It causes whooping cough or pertussis in humans, which is the most prevalent vaccine-preventable disease worldwide. (pasteur.fr)
  • Despite high-levels of vaccination, whooping cough, primarily caused by Bordetella pertussis (BP), has persisted and resurged. (biorxiv.org)
  • For many people, pertussis (commonly known as Whooping Cough) is old news-a once-feared disease long controlled by vaccination. (breezymama.com)
  • Pertussis or whooping cough has persisted and resurged in the face of vaccination and has become one of the most prevalent vaccine-preventable diseases in Western countries. (cambridge.org)
  • Whooping cough, or pertussis, gets its name from the "whoop" sound that a person (typically a child) makes when he or she gasps for air after a coughing fit. (livescience.com)
  • Research shows that children under the age of six months have the highest burden of respiratory diseases such as influenza and whooping cough, known as pertussis . (news24.com)
  • Bordetella pertussis is the agent responsible for whooping cough, a disease that is currently on the rise. (pasteur.fr)
  • So the term 'whooping cough' comes essentially from the sound that a person that suffers from pertussis disease makes while coughing. (cdc.gov)
  • It is noteworthy that the number of CD4 T lymphocytes has decreased in the laboratory findings of whooping cough, and that some medicines used in treatment (Chloroquine, erythromycin) can also be used in Bordetella species. (ejmo.org)
  • Guris D , Strebel PM , Bardenheier B , Brennan M , Tachdjian R , Finch E , Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. (cdc.gov)
  • It means that pertussis is reappearing again with increasing incidence rates despite the high vaccination coverage, of course, in most of the countries. (cdc.gov)
  • However, genome data of B. pertussis is rare in India due to the complexity of culturing B. pertussis from clinical samples. (jgenomics.com)
  • 0.94 IV or less: Negative - No significant level of detectable B. pertussis IgG antibody. (aruplab.com)
  • If Bordetella pertussis Antibody, IgG by ELISA is 1.05 IV or greater, then Bordetella pertussis IgG Immunoblot testing will be added. (aruplab.com)
  • Here we describe pertussis epidemiology in Argentina during 2006-2008 and discuss possible reasons for increase.Methods: CDC criteria were used for pertussis diagnosis. (conicet.gov.ar)
  • Severe pertussis infections in the United States, 2011-2015. (cdc.gov)
  • Disease relevance of brk A We have recently observed that a B. pertussis strain, putatively with a mutation of a single gene, brk A, results in a severe defect in vivo. (wikigenes.org)
  • test does not determine immunity to B. pertussis . (aruplab.com)
  • Pathogenesis and immunity in pertussis / edited by Alastair C. Wardlaw and Roger Parton. (who.int)
  • The increase in pertussis is mainly found in age groups in which immunity has waned and this has resulted in the perception that waning immunity is the main or exclusive cause for the resurgence of pertussis. (cambridge.org)
  • The introduction of the pertussis whole-cell vaccination for young children, followed by the introduction of the pertussis acellular vaccination (along with booster vaccination) for older age groups, has affected the bacterial population and epidemiology of the disease. (pasteur.fr)
  • All students had received a full course of pertussis whole-cell vaccination at ages 2, 4, 6 and 18 months and 4-6 years. (who.int)
  • Tan T , Trindade E , Skowronski D . Epidemiology of pertussis. (cdc.gov)
  • These studies illustrated that genome evolution in B. pertussis is mainly due to rearrangement in addition to genome reduction [ 2 ]. (jgenomics.com)
  • Pasteurian Contributions to the Study of Bordetella pertussis Toxins. (bvsalud.org)
  • As a tribute to Louis Pasteur on the occasion of the 200th anniversary of his birth , this article summarizes the main contributions of scientists from Pasteur Institutes to the current knowledge of toxins produced by Bordetella pertussis . (bvsalud.org)
  • The article therefore focuses on publications authored by researchers from Pasteur Institutes and is not intended as a systematic review of B. pertussis toxins. (bvsalud.org)
  • Several antigenic components of Bordetella pertussis have been identified. (cdc.gov)
  • B. pertussis is relatively monomorphic worldwide, but nevertheless, different countries are facing different epidemiological evolutions of the disease. (pasteur.fr)
  • Adults who have been vaccinated against pertussis may have more mild symptoms of the disease, and so they may think they have a regular cold and not go to the doctor, Jordan-Villegas said. (livescience.com)
  • If pertussis is spreading in an area, there is a chance that a person who has had the vaccine can still catch the disease. (ahealthyme.com)
  • View the Pertussis Disease Villain's rap sheet below to find out more about this public health nemesis. (cdc.gov)
  • Pertussis can also pull off its own complications among young children, such as pneumonia, seizures, and encephalopathy (disease of the brain). (cdc.gov)
  • The PCR method was more efficient than culture in detecting B. pertussis in samples collected late in the disease, in antibiotic-treated children and in patients with mild disease. (microbiologyresearch.org)
  • The challenge is that although babies start their pertussis vaccinations when they are six weeks old, they are only protected against the disease after their third dose of the vaccine when they are three months old. (news24.com)
  • This disease can be mostly prevented with the pertussis vaccine. (childrenshospital.org)
  • Background and aims: Pertussis is a vaccine-preventable disease caused by Bordetella pertussis. (conicet.gov.ar)
  • Sarah Gregory] Your paper refers to pertussis as a reemerging disease. (cdc.gov)
  • Isolation and characterization of catalytic and calmodulin-binding domains of Bordetella pertussis adenylate cyclase. (archives-ouvertes.fr)
  • Tracking Pertussis and Evaluating U.S. Control Measures through the Emerging Infections Program Network's Enhanced Pertussis Surveillance System. (cdc.gov)
  • Inflammation and infections as risk to prevent and control pertussis, but in many coun- factors for ischemic stroke. (cdc.gov)
  • Also, other bacterial infectors just love to join pertussis' party, moving into a sick person's pertussis-infected lungs to cause their own infections. (cdc.gov)
  • Our study proved that the women who received the influenza vaccine had less pertussis infections. (news24.com)
  • Using a Bordetella IgG ELISA kit, pertussis-IgG was detected in 301 (47.0%) students. (who.int)
  • Genomic Survey of Bordetella pertussis Diversity in the United States, 2000-2013. (cdc.gov)
  • Changes in genetic diversity of the Bordetella pertussis population in the United Kingdom between 1920 and 2006 reflect vaccination coverage and emergence of a single dominant clonal type. (cdc.gov)
  • Resurgence of pertussis in Europe. (cdc.gov)
  • The suspected pertussis cases, reported by health workers from the Ononge health centre area, were investigated and confirmed for the presence of Bordetella pertussis DNA using the polymerase chain reaction (PCR) method. (who.int)
  • Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence? (cdc.gov)
  • Pertussis is highly infectious and can cause serious complications, especially in babies, so people should take it seriously," Cornelius said. (go.com)